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Abstract: 
 
Leukemia disease like chronic myelogenous leukemia (CML) and acute lymphoblastic 
leukemia (ALL)  is believed to be induced by  a reciprocal translocation between the long 
arms of chromosomes 9 and 22, t(9:22), ending with a characteristic philadelphia chromosome 
generating a chimeric Bcr-Abl gene. Recognizing Bcr-Abl as the major leukemogenenis key 
player in 80% CML and 20% ALL initiated several trials to develop selective Bcr-Abl 
inhibitors as means for treating leukemia. The vast majority of known Bcr-Abl kinase 
inhibitors are ATP competitors that bind to the kinase domain. Despite the profound success in 
employing ATP competitors as potent anti-leukemogenic agents, resistance due to kinase 
domain mutant emerged as main limiting factors hindering patient cure. Among tens clinically 
relevant mutants the ‘gatekeeper’ T315I confers complete resistance to Abl kinase inhibitors.  
Recently, the discovery of two lead compounds GNF-2 and GNF-5 as selective non-ATP 
competitive inhibitors constitutes a new potential approach to the treatment of CML, these 
compounds were demonstrated to possess cellular activity against Bcr-Abl transformed cells 
by targeting the myristate binding site, also it was proved that these compounds can act 
cooperatively with an ATP-competitive inhibitor to suppress many mutations at the Bcr-Abl 
kinase domain especially the recalcitrant ‘‘T315I’’ gatekeeper mutant. 
 
In the present work we focused on the regulatory myristoyl binding pocket as the postulated 
GNF-2 /-5 binding site. Accordingly, three groups of compounds have been designed, 
synthesized, purified using chromatography techniques, characterized by (1H-NMR, 13C-
NMR, FT-IR and ESIMS) spectroscopy and tested for their biological activity against Ba/F3 
harboring native and T315I Bcr-Abl. 
 
Our results demonstrated that MYJ-1 (20), MYJ-2 (16) and MYJ-17 (29) exhibited limited 
activities against Ba/F3 P185 tyrosine kinase and that MYJ-16 (28) showed improved activity 
that is concentration dependent compared to GNF-2 (8). Compound 28 showed comparable 
activity against clonigenicity of Ba/F3 harboring native and T315I Bcr-Abl constructs at 
concentration of 25 µM. It was shown that compound 28 was more active in inhibiting 
iv

proliferation of ALL cell lines Sup-B15 at lower concentrations compared to MYJ-18 (30) and 
MYJ-19 (31).  
This work demonstrates that a variety of structures can effectively inhibit Bcr-Abl by 
presumably targeting myristate binding pocket and provides new leads for developing drugs to 
treat Bcr-Abl driven leukemia.  
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Chapter One 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 

1. Introduction: 
 
1.1 Protein Kinases and their role in Cancer: 
 
Protein kinases are class of cellular enzymes that contain an ATP-dependent catalytic activity 
results in the covalent attachment of a phosphate group to serine, threonine or tyrosine residues 
in specific peptide sequences of substrate proteins. There are an estimated 518 protein kinases 
encoded by the human genome, which are divided into two main groups on the basis of structural 
relatedness [1-3]. 
Those predicted 518 protein kinases are involved in mediating important events in normal cells 
such as: proliferation, cell cycle, metabolism, survival, apoptosis, DNA damage repair, cell 
motility and response to the microenvironment [4]. 
Several biochemical and genetic studies have revealed essential roles for many of the 518 human 
protein kinases in a broad range of diseases, where aberrant signals transduction processes have 
been identified. Therefore selective inhibition of distinct members of that target family offers 
novel opportunities for drug discovery and development for numerous diseases, including 
various cancer types, inflammatory, cardiovascular, metabolic, neurodegenerative, and even viral 
and bacterial diseases [5]. 
Kinases such as cellular sarcoma (c-Src) kinase, Abelson Leukemia Virus (c-Abl) kinase, 
mitogen activated protein (MAP) kinase, phosphotidylinositol-3-kinase (PI3K), and the 
epidermal growth factor receptor (EGFR) are commonly activated in cancer cells. They play a 
central role in the growth and proliferation of tumor cells, hence making them a legitimate target 
for new anti-cancer drugs [6-8].  
The benefit of using kinase inhibitors as anti-cancer drugs stems from the fact that they would be 
more specific than traditional chemotherapeutic agents, effectively targeting active tumor cells 
without affecting the rapid growth of healthy cells found in the bone marrow and gastrointestinal 
tract as example.  The traditional chemotherapeutic agents typically inhibit the growth of all 
rapidly dividing cells, including non-tumor cells, which is why they cause a multitude of 
unwanted side effects.  Another benefit of using kinase inhibitors is their good tolerability and 
oral bioavailability compared to the traditional cytotoxic agents currently in use.   

Nevertheless, kinases are also involved in the growth of healthy cells and finding an agent that 
selectively inhibits tumor kinases with high efficacy is not an easy task.  The main challenge 
stems from the lack of sufficient research to identify the kinases that are pathologically activated 
in a particular disease setting; also drug resistance is a significant challenge that faces the field, 
until such information becomes available it would be difficult to find a selective and efficacious 
kinase inhibitor [8, 9]. To date, more than 14 kinase inhibitors have received US Food and Drug 
Administration approval as cancer treatments, see Table 1.1 below [10-12]. 
 
Table 1.1: List of 14 kinase inhibitors approved to date for various cancer indications within the 
U.S. since 2001: 
 
U.S. 
brand 
name 
 
Year 
appr
oved 
Generic 
name 
U.S. FDA-approved 
indications 
Company Target kinases 
Gleevec 
 
2001 
 
 
Imatinib 
mesylate 
CML, GIST, HES Novartis 
Bcr-Abl, c-
Abl, c-Kit, 
PDGFR, 
DDR1 
 
Iressa 
 
2003 
 
Gefitinib NSCLC AstraZeneca EGFR, HER-4 
Tarceva 2004 Erlotinib 
NSCLC, pancreatic 
cancers 
Genentech, OSIP, 
Roche 
EGFR 
Nexavar 2005 
 
Sorafenib 
tosylate 
 
HCC, RCC Bayer and Onyx 
Raf, VEGFR, 
c-Kit, PDGFR 
Sutent 2006 
Sunitinib 
malate 
 
GIST, RCC 
 
Pfizer 
c-Kit, VEGFR, 
PDGFR, FLT3 
Sprycel 2006 
 
Dasatinib 
 
CML (especially 
imatinib-resistant) 
Bristol-Myers 
Squibb 
Bcr-Abl, c-
Abl, c-Kit, 
PDGFR, Src 
Tasigna 2007 Nilotinib 
CML (imatinib 
resistant 
and intolerant) 
Novartis 
Bcr-Abl, c-
Abl,  c-Kit, 
PDGFR,Src, 
Ephthrin 
Tykerb 2007 Lapatinib breast cancer GlaxoSmithKline EGFR, HER-2 

Table 1.1, cont.: 
Votrient 2009 Pazopanib 
Advanced RCC, 
STS 
GlaxoSmithKline 
VEGFR-1, -2, 
and -3, 
PDGFR, c-Kit 
Caprelsa 2011 Vandetanib 
Unresectable, locally 
advanced, or 
metastatic MTC 
AstraZeneca 
VEGFR,  
EGFR 
Zelboraf 2011 Vemurafenib 
Unresectable or 
metastatic melanoma 
carrying the mutant 
BRAFV600E 
Roche 
BRAf 
 
Xalkori 2011 
Crizotinib 
 
Locally advanced or 
metastatic NSCLC 
Pfizer ALK, ROS1 
Bosulif 2012 Bosutinib 
chronic, accelerated, 
or blast phase 
Ph+CML with 
resistance 
Pfizer 
Src, Bcr-Abl, 
c-Abl 
Iclusig 2012 Ponatinib 
CML with T3151 
mutation,  Ph+ALL 
Ariad 
Pharmaceuticals 
Bcr-Abl, 
FLT3, RET, c-
Kit, members 
of the EGFR, 
PDGFR and 
VEGFR 
families of 
kinases. 
 
Abbreviations: CML, chronic myeloid leukemia; GIST, gastrointestinal stromal tumours; HES, 
hypereosinophilic syndrome; NSCLC, non-small-cell lung cancers; RCC, renal cell carcinoma; 
HCC, hepatocellular carcinoma; STS, soft tissue sarcoma; MTC, medullary thyroid cancer; 
Ph+CML, Philadelphia chromosome-positive chronic myelogenous leukemia; Ph+ALL, 
Philadelphia chromosome positive Acute Lymphoblastic Leukemia. Bcr-Abl, breakpoint cluster 
region-Abelson kinase; c-Abl, Abelson Leukemia Virus kinase; c-Kit, Proto-oncogene tyrosine-
protein kinase Kit; PDGFR, platelet-derived growth-factor receptor; DDR1, discoidin domain 
receptor tyrosine kinase 1; EGFR, epidermal growth-factor receptor; HER-4, Receptor tyrosine-
protein kinase erbB-4; Raf, proto-oncogene serine/threonine-protein kinase; VEGFR, vascular 
endothelial growth-factor receptor; HER-2, human epidermal growth factor receptor-2; Flt3, FL 
tyrosine kinase 3; Src, Proto-oncogene tyrosine-protein kinase; BRAf, v-raf murine sarcoma 
viral oncogene homolog B1; RET, rearranged during transfection proto-oncogene; ALK, 
anaplastic lymphoma kinase; ROS1, c-ros oncogene1 receptor tyrosine kinase.  
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1.2 Tyrosine Kinases (TKs): 
 
Tyrosine kinases are a family of tightly regulated phosphotransferase enzymes which transfer 
phosphate groups from high energy donors, such as ATP, to substrates bearing a tyrosine 
residue. In the human genome, 90 tyrosine kinases have been identified, and are divided into two 
groups, receptor and nonreceptor [13, 14].   
There are 58 known receptor kinases which are subdivided into 20 subfamilies. Examples of 
such kinases include the epidermal growth factor receptor (EGFR), platelet-derived growth 
factor receptor (PDGFR), vascular endothelial growth factor (VEGF) receptor and c-kit/stem cell 
factor receptor.  All the receptor kinases function in a similar fashion by transducing signals from 
both outside and inside the cell and serving as relay points for signaling pathways inside the cell. 
On the other hand, the 32 remaining tyrosine kinases are cytoplasmic non-receptor type which 
lack a transmembrane segment and generally function downstream of the receptor tyrosine 
kinases. Examples of such non-receptor kinases include the breakpoint cluster region-Abelson 
kinase (Bcr-Abl) fusion protein and c-Src [15, 16]. 
Tyrosine kinases play a critical role in the signaling cascades; their strict regulation of activity 
controls the most fundamental processes of cells, such as, cell proliferation, migration, 
differentiation, metabolism and programmed cell death.  
Recent advances showed a primary role of tyrosine kinases in the pathophysiology of cancer. 
Though their activity is tightly regulated in normal cells, they may acquire transforming 
functions due to mutations, overexpression or other reasons, leading to malignancy.  The central 
role that tyrosine kinases, receptor and nonreceptor alike, play in tumorgenesis makes them 
primary targets for future cancer therapies.  Examples of such kinases include Abl, Src, EGFR, 
PDGFR and VEGFR families [17-19]. 
 
One such kinase is the Abelson Leukemia Virus kinase (c-Abl) which is a nonreceptor tyrosine 
kinase.  Human cells express two spliced variants of this kinase; one is myristoylated at the N-
terminal (Abl-1b) while the other is not (Abl-1a).  The c-Abl kinase is approximately ~1150 
residues long with a unique ~80 residue N-terminal cap thought to be important for 
autoinhibition of c-Abl. Following the N-terminal cap, there are Src Homology 3 (SH3), Src 
Homology 2 (SH2) and tyrosine kinase domains (Figure 1.1).  The C-terminal half of c-Abl 

contains nuclear localization and export signals, binding elements for the SH3 domains as well 
as DNA binding and actin binding domains [20-23]. 
 
 
Figure 1.1: The domain structure of the enzymes Abl 1a and 1b [16]. 
 
1.3 Modes of activation of c-Abl tyrosine kinase: 
 
The c-Abl tyrosine kinase is composed of a two-lobe enzymatic domain (catalytic site), with a 
smaller lobe containing an -helix (C-helix) polypeptide segment and a larger lobe containing 
the “activation loop” polypeptide segment which is stabilized in its active form by 
phosphorylation. The aforementioned catalytic site lies in a cleft between the smaller amino 
terminal and the carboxy terminal and can open or close the active site by adopting a range of 
relative orientations [23]. The kinase control-machinery is composed of three critical components: 
the “switch”, the “clamp” and the “latch”. The “switch” is the “activation loop” which lies in the 
larger C-lobe while the “clamp” is an assembly of the SH2 and SH3 domains abutting both the 
C-lobe and the smaller N-lobe respectively (Figure 1.2; (a)).  The SH2 domain is connected to 
the kinase via an adapter element which runs through the ligand-binding groove of the SH3 
domain.  Finally, the “latch” is the short C-terminal tail of the larger C-lobe [24-26].   
Switching the kinase on begins with the “latch” which releases the “cap” that extends from the 
SH3 domain abutting the N-terminal and which is anchored by a myristoyl group to the C-lobe.  
Activation of the kinase is finally achieved by phosphorylation of a tyrosine in the “activation 
loop” after the SH2 and SH3 ligands (regulatory apparatus) are unclamped (Figure 1.2; (b)) [27, 
28]. 
 

  
 
Figure 1.2: (a) The order of domains in the polypeptide chains of c-Abl and diagram of its 
assembled, autoinhibited state [26], (b) Modes of Activation for c-Abl: unlatching, 
unclamping, and switching [26]. 
 
1.4 Chronic myelogenous leukemia (CML): 
 
Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disorder of 
haematopoietic stem cells, characterized by the increased and unregulated growth of myeloid 
cells in the bone marrow and the accumulation of these cells in the blood. It accounts for 15–20% 
of all cases of leukemia with an annual incidence of 1–2 cases per 100,000 individuals per year.  
Clinically, the disease progresses through three distinct phases, the first chronic or stable phase 
which is characterized by increased number of myeloid precursors and mature cells that leave the 
bone marrow prematurely but retain their ability to differentiate normally. Within a period of 4–6 
years, the disease transforms to the second accelerated phase which is characterized by the 
presence of primitive blast cells in the bone marrow and peripheral blood, and finally the disease 
advances to the fatal ‘blast-crisis’ phase, characterized by over 30% undifferentiated blasts in the 
bone marrow and peripheral blood, where median survival is 18 weeks nearly [29-31]. 
 
The majority of CML patients are diagnosed by the presence of philadelphia chromosome (Ph), 
which results from a reciprocal translocation between the long arms of chromosomes 9 and 22, 
t(9:22), which generates a chimeric Bcr-Abl gene, formed by juxtaposition of the c-Abl 
oncogene on chromosome 9 with sequences from the breakpoint cluster region (Bcr) on 
chromosome 22.   
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There are multiple points along the Bcr-Abl genes at which a break can produce a chimeric 
fusion protein. For instance, the fusion of c-Abl proto-oncogene between the first and second 
exons will result in the p210 Bcr-Abl fusion genes which transcribe either a b2a2 or b3a2 
mRNA, the product of which is a 210 kDa cytoplasmic fusion protein sufficient for the 
malignant transformation and phenotypic abnormalities seen in the vast majority of CML 
patients. Additionally, half of (Ph) positive Acute Lymphoblastic Leukemia (ALL) adults 
reportedly carry the p210 fusion genes while the other half bears the p185 Bcr-Abl (also called 
p190) product which results from fusion of the same sequences of c-Abl with a proximal site in 
Bcr (exon 1). The p185 Bcr-Abl product is also found in up to 80% of Ph-positive children 
suffering with ALL (Figure 1.3) [32-35].  
 
 
 
Figure 1.3: (a) Locations of the breakpoints in the c-Abl and Bcr genes and structure of the 
chimeric Bcr-Abl mRNA transcripts derived from the various breaks [31], (b) Domain 
structure of c-Src, c-Abl 1b, and Bcr-Abl. Potential tyrosine phosphorylation sites 
are indicated with red circles and the residue number [21]. 
 
1.5 Signaling pathways activated by Bcr-Abl: 
 
In contrast to ABL which normally exists in an inactive conformation, Bcr-Abl oncogene 
encodes a chimeric Bcr-Abl protein that exhibits deregulated aberrant Abl tyrosine kinase 
activity and is found exclusively in the cytoplasm of the cell, complexed with a number of 
cytoskeletal proteins. 
This mutant kinase increased activity is due to two reasons: 
1- The fusion protein retains most Abl coding sequences, but deletes the myristoylation site 
from the extreme N terminus of Abl, thus “unlocking” the closed, inactive conformation.  

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2- Sequences from Bcr also contribute to fusion protein activity, where most studies agree 
that the N-terminal Bcr dimerization domain, present in both fusion proteins, disrupts the 
autoinhibited “closed” conformation and promotes transautophosphorylation and kinase 
activation.  
The constitutive tyrosinekinase activity of Bcr-Abl causes activation of a cascade of intracellular 
signaling pathways, in a kinase-dependent manner, leading to increased proliferation, increased 
resistance to apoptosis and an alteration of their adhesion properties, and thus the activation of 
such pathways may affect the expression of genes that confer the malignant phenotype.  
Signal transduction pathways activated by p210 Bcr-Abl are: Ras/Raf/mitogen activated protein 
kinase (MAPK), phosphatidylinositol 3 kinase (PI3-kinase), STAT5/Janus kinase, and Myc 
(Figure 1.4) [36-40].  
 
 
 
Figure 1.4: Cellular outcomes of activated pathways by Bcr-Abl [40]. 
 
 
Much of the knowledge regarding the function of this gene, the growing understanding of 
genetic alterations and the identification of the molecules that are part of the signaling cascade in 
CML cells, prompted searching for a specific inhibitor of the Bcr-Abl tyrosine kinase that would 
be effective and selective therapeutic agent for targeting various steps of the malignant 
transformation. 
 

1.6 Therapeutic approaches targeting Bcr-Abl kinase for the treatment of CML: 
 
1.6.1 ATP-competitive inhibitors of Bcr-Abl: 
 
As CML arises from a single genetic lesion, a research goal has been to develop kinase-specific 
inhibitors, and after performing a high-throughput screening of chemical libraries searching for 
compounds with kinase inhibitory activity, a lead compound of the 2-phenylaminopyrimidine 
class was identified, Imatinib mesylate (also known as STI-571 and Gleevec) which is selective 
for two protein kinase receptors, the PDGFR and c-Kit, and a non-receptor TK, the Abl, where it 
behaves as an ATP-competitive inhibitor of it (Figure 1.5) [41-43]. 
 
Lead from random screening
2-phenylaminopyrimidine scaffold
IC50 = 1µM
simple synthesis
ATP-competitive
Strong inhibition of autophosphorylation of: Abl, PDGFR, Kit
v-Abl IC50 = 0.1-0.3 µM
Bcr–Abl IC50 = 0.25 µM
PDGFR and c-Kit IC50 = 0.1 µM
10 steps synthesis
ATP-competitive
Salts water soluble
Orally bioavailable
FDA approval 2001
OPTIMIZATION
> 300 compounds
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Figure 1.5: Imatinib development. 
 
Clinically imatinib is very successful in treating Bcr-Abl positive leukemias, and thus considered 
as an effective and selective frontline therapy for chronic-phase CML, that binds to the catalytic 
cleft between the two N and C-lobes via six hydrogen bond interactions, thus stabilizing the 
kinase in an inactive conformation referred to as the ‘DFG-out’ conformation, in which the 
highly conserved aspartate-phenylalanine-glycine (DFG) triad is flipped out of its usual position 
in active kinase conformations with the activation loop in a closed position and P-loop 
(phosphate-binding loop) folding over the ATP binding site (Figure 1.6; (a)) [10, 12, 44, 45]. 
 

  
Figure 1.6: Structural features of the Abl kinase domain important for activity and inhibitor 
binding.  
(a)  Close-up view of the Abl kinase domain bound to imatinib, which stabilizes a 
down regulated conformation of the active site. Key structural elements of this off 
state include the inward rotation of the N-lobe C-helix (cyan), which positions 
Glu286 for ion pairing with Lys271. The DFG motif (Asp381, Phe382, Gly383), 
which is located at the N-terminal end of the activation loop (Act Loop; green), is 
rotated away from the active site to accommodate imatinib binding (DFG-out). The 
activation loop tyrosine (numbered as Tyr393 in this structure) points into the active 
site and makes a hydrogen bond with the catalytic aspartate (Asp363; purple). Also 
shown is the side chain of the gatekeeper residue (Thr315; orange) which forms a 
critical hydrogen bond with imatinib [45], (b) Close-up view of the Abl catalytic site 
in an active conformation with dasatinib bound (ligand carbon atoms in yellow). 
Note that the C-helix and the Glu286 ion pair with Lys271 are positioned as per the 
inactive state in a, but the activation loop is completely reoriented. The 
phosphorylated activation loop tyrosine (pTyr393) is now paired with a nearby 
arginine residue (Arg386), releasing the catalytic aspartate and stabilizing the active 
conformation. The DFG motif is now flipped inward (DFG-in); this conformation is 
not compatible with imatinib binding due to steric clash. The gatekeeper threonine 
also makes an H-bond with dasatinib [45]. 
 
However, accelerated or blast-crisis phase CML and Ph+ ALL patients often relapse due to drug 
resistance results from amplification  or overexpression of the Bcr-Abl gene, or by  the 
emergence of point mutations within the kinase domain of the Bcr-Abl protein, which  
frequencies appear to increase as the disease progresses [10].  
These point mutations either prevent the appropriate binding of imatinib (loss of response or 
acquired resistance) by disrupting hydrogen bonds between the drug and the Abl protein or 
leading to a steric clash or hindrance, which is the case with T315I (gatekeeper) that precludes 
imatinib from binding; or reduce the binding affinity of imatinib (lack of response or primary 

resistance) by either preventing necessary conformational adjustments for imatinib binding, 
which is the case with Y253F/H and E255K/V, or stabilizing the active kinase conformation, 
from which imatinib is sterically excluded, which is likely the mechanism of resistance of 
M351T [46-48]. Most mutations that confer resistance to imatinib are distributed throughout the 
Abl kinase domain. However, the most resistant ones are found in the P-loop at or near residues 
that are in direct contact with the drug (Figure 1.7) [49, 50].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: A range of Bcr-Abl kinase domain mutations identified including mutations in each 
of the three functional regions of Bcr-Abl, the p-loop region, the catalytic domain 
and the activation domain. 
 
1.6.2 Second Generation ATP-Competitive Bcr-Abl Inhibitors: 
 
Due to the resistance to Imatinib in blast-crisis phase CML, there is an urgency to develop novel 
compounds to prevent or overcome this resistance, the elucidation of the mechanisms of 
resistance has enabled the rational development of new ATP-competitive Bcr-Abl novel agents 
such as: 
 
1.6.2.1 Nilotinib (AMN107): The substitution of the amide moiety in imatinib with an 
alternative binding group, led to the discovery of nilotinib (Figure 1.8; (2)). Like imatinib, 
nilotinib binds to the inactive conformation of the Abl tyrosine kinase by making four hydrogen 
bond interactions. Nilotinib is 10 to 30 times more potent than imatinib in inhibiting the 
proliferation and autophosphorylation of wild-type Bcr-Abl cell lines and is also significantly 

active against 32/33 imatinib-resistant Bcr-Abl mutants, except the T315I mutant, which is 
situated in the middle of the ATP-binding cleft [51-53]. 
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Figure 1.8: The chemical structures of (1) Imatinib, (2) Nilotinib, (3) Dasatinib, (4) Bosutinib  (5)   
                    Ponatinib (6) Bafetinib (7) ON012380, (8) GNF-2, and (9) GNF-5. 
 
1.6.2.2 Dasatinib (BMS-345825): A thiazolylaminopyrimidine core derivative which is a multi-
target kinase inhibitor of Bcr-Abl and Src family kinases (Figure 1.8; (3)). Comparing with 
imatinib, dasatinib has an approximately 325-fold increased potency in proliferation assays of 
Bcr-Abl expressing cell lines and biochemical assays [54]. Unlike imatinib and most tyrosine 
kinase inhibitors (TKIs), dasatinib target the ATP binding site of the Abl kinase in its active 
conformation, in which the activation loop is phosphorylated (DFG-in) (Figure 1.6; (b)), but with 
less stringent conformational requirements, so it exhibits increased potency but reduced 
selectivity compared to imatinib. Also it can inhibit all Bcr-Abl kinase domain mutants except 
for T315I [9, 55, 56]. 
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1.6.3 Third generation ATP-Competitive Bcr-Abl Inhibitors: 
 
However, since the T315I mutation of Bcr-Abl is highly resistant to the first and second 
generations of TKIs and still unconquered, this approach needs to be extended to include more 
inhibitors of T315I Bcr-Abl to prevent it from becoming more prevalent. Some of more new 
drugs are in development, which are either refining current treatments or promising great 
improvements in efficacy, such as: 
 
1.6.3.1 Bosutinib (SKI-606): Bosutinib inhibits Src, Abl and a wide range of both tyrosine and 
serine-threonine kinases (Figure 1.8; (4)). However, the T315I mutation was completely resistant 
to bosutinib [57-59]. 
 
1.6.3.2 Ponatinib (AP24534): Ponatinib has been proved as a potent drug and targets not just 
most of the known mutations on the Bcr-Abl TK but, most importantly of all, T315I. The reason 
was referred to the linearity of the linkage section of the molecule by which the drug appears to 
avoid steric hindrance with hydrophobic TK gatekeeper residues [60-63]. 
This agent is marketed as a second line therapy (Figure 1.8; (5)). 
 
1.6.3.3 Bafetinib (INNO-406): Bafetinib is a multi-target kinase inhibitor of Bcr-Abl and Src 
family kinases Lck and Lyn; with unrivalled specificity, also it is effective against most of 
imatinib resistant mutations (not including T315I) and some dasatinib resistant mutations. 
Bafetinib has more affinity for Bcr-Abl than nilotinib (but less than dasatinib). However, this 
agent is in phase II clinical trials (Figure 1.8; (6)) [64-67]. 
Refer to Table 1.2. 
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Table 1.2: ATP-competitive inhibitors of Bcr-Abl summary: 
 
Drug H-bonds 
H-bonding 
amino acids 
Binding 
conformation 
Discovery Status 
Imatinib 
(STI571) 
6 
Met-318, 
Thr-315, 
Glu-286, 
Asp-381, 
Ile-380, 
His-361 
Inactive 
Drug 
screening 
Marketed 
as first line 
therapy 
Nilotinib 
(AMN107) 
4 
Met-318, 
Thr-315, 
Glu-286, 
Asp-381 
Inactive 
Rational 
drug 
design 
Marketed 
as second 
line 
therapy 
Dasatinib 
(BMS-345825) 
3 
Met-318, 
Thr-315 
Active 
Rational 
drug 
design 
Marketed 
as second 
line 
therapy 
Bosutinib 
(SKI-606) 
- - Inactive 
Rational 
drug 
design 
Marketed 
as second 
line 
therapy 
Ponatinib 
(AP-24534) 
5 
Met-318, 
Asp-381, 
Glu-286, 
His-381, 
Ile-380 
Inactive 
Rational 
drug 
design 
Marketed 
as second 
line 
therapy 
Bafetinib 
(INNO-406) 
6 
Met-318, 
Thr-315, 
Glu-286, 
Asp-381, 
His-361, 
Ile-360 
Inactive 
Rational 
drug 
design 
Phase II 
clinical 
trials 
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1.6.4 Non- ATP-competitive inhibitors of Bcr-Abl: 
 
1.6.4.1 Substrate binding inhibitors:  
 
Beside the ATP-binding site that has been traditionally targeted by medicinal chemists, the 
ligand binding site also was validated as targetable and a novel compound ON012380 was 
identified. The specific inhibitor of Bcr-Abl substrate binding ON012380, (amino-substituted 
(E)-2,6-dialkoxystyryl 4-substituted- benzylsulfone  derivative (Figure 1.8; (7)), was proved to 
inhibit T315I- Bcr-Abl transformed leukemia cells through a distinct mechanism. However, this 
agent has not been tested in clinical studies yet (Figure 1.9) [68-70]. 
 
1.6.4.2 Allosteric binding inhibitors:  
 
Allosteric inhibitors are the third class of compounds. These inhibitors bind at an allosteric site 
apart from the ATP catalytic active site where it modulates kinase activity in an allosteric 
manner involving a conformational change between active and inactive states of the protein. 
Inhibitors belonging to this category are characterized to exhibit the highest degree of kinase 
selectivity because they exploit binding sites and regulatory mechanisms that are unique to a 
particular kinase, also these inhibitors offer an alternative approach to inhibition of protein 
activities, particularly for proteins that undergo conformational changes as part of their activity 
cycle, and are regulated by autoinhibition [71]. 
Studies showed that the ATP-competitive inhibitors must bind with relatively higher affinity or 
be present at higher concentrations to effectively compete with the binding of naturally occurring 
substrates, whereas in contrast, a small molecule allosteric inhibitor may recognize a target site 
allowing effectiveness at substantially lower concentrations. Furthermore, enzyme active sites 
are highly conserved across large protein families (e.g., kinases, proteases), making the 
identification of inhibitors specific to a particular family member problematic because of cross-
reactivity. In contrast, binding sites for potential allosteric inhibitors, involving sequences distant 
from the catalytic site, can vary significantly among the members of a protein family [72-74]. 
Abl possesses a deep hydrophobic pocket that can bind fatty acid chains such as myristoyl 
groups (a small hydrophobic chain of 14 carbons). Studies revealed that myristoylation of the N-
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terminal region of wild-type Abl is involved in the regulation of the enzymatic activity by 
altering the protein conformation by inserting the myristate group into the hydrophobic pocket of 
the kinase domain (Myristoyl binding pocket-MBP). On the contrary, Bcr-Abl where N-terminal 
is replaced by the Bcr segment is not myristoylated and lacks this autoinhibitory mechanism. 
Hence it is believed that this Bcr-Abl translocation resulted in the absence of on control 
mechanism which rationalizes the idea of the strategy to develop inhibitors for the MBP 
“myristoyl mimics”. Such inhibitors if manage to bind to the MBP which located in the C lobe of 
the kinase more than 30 Å away from the active site in a selective manner, will induce the 
essential conformational changes to inhibit the kinase activity via binding to allosteric, non-ATP 
competitive mechanism, distant from the active site of the kinase (Figure 1.9) [75-77].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: GNF-2, Imatinib and ON012380 binding to different binding sites in the kinase domain [75]. 
 
A recent cell based high-throughput screen identified novel 4,6-disubstituted pyrimidine  
derivatives with  potent and selective inhibitory activity to Bcr-Abl. These compounds were 
proved to be not competitors with either the substrate or ATP, but the binding site of these 
inhibitors is the myristoyl pocket. This new class of Abl inhibitor could allow synergistic 
treatment with active-site inhibitors. 
GNF-2 [3-(6-(4-(trifluoromethoxy) phenylamino) pyrimidin-4-yl) benzamide] (Figure 1.8; (8)), 
was discovered by Nathanael S. Gray and his colleagues and proved to be a potent and selective 
inhibitor of cellular proliferation. Using a differential cytotoxicity assay and screening a 
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combinatorial library of 50,000 heterocycles originally designed to target the ATP binding site 
GNF-2 identified as novel lead for MBP ligand.  
GNF-2 specifically inhibited the proliferation, induced apoptosis and inhibited the 
autophosphorylation of the Bcr-Abl expressing cells with IC50 of 138 nM and did not show any 
cytotoxic effects on the nontransformed cells at concentrations up to 10 µM [78, 79].  
Using solution NMR, X-ray crystallography, mutagenesis and hydrogen exchange mass 
spectrometry, it was shown that GNF-2 binds to the myristate-binding site of Abl located near 
the C-terminus of the kinase domain, where it seems to stabilize the inactive conformation of 
Bcr-Abl by inducing the bending of the kinase domain -I helix (which is extended and clashes 
with the SH2 domain when the myristoyl pocket is not occupied) toward the C-lobe, allowing the 
SH2 domain to dock to the C-lobe. Subsequently, the SH3 domain can dock to the N-lobe, 
disrupting the catalytic machinery located in the ATP-binding site and holding the kinase in an 
inactive state (Figure 1.10 (a)) [80-82]. 
 
 
Figure 1.10:(a) Schematic representation of the mechanism of action of Bcr-Abl/c-Abl myristate 
pocket binders. The SH3, SH2 and kinase domains are shown in yellow, green and blue, 
respectively. The myristoyl group that is attached to the N-terminus of c-Abl binds to a 
deep hydrophobic pocket in the kinase domain and induces bending of the C-terminal I'-
helix (shown in dark red. Next to the schematic representations, a blow-up shows the 
myristate pocket from the crystal structures of the Abl kinase domain alone and in 
complex with myristate, GNF-2 [82], (b) Binding conformation of GNF-2 (cyan) in the 
myristate binding site of Abl (side chains from helix E are green, F orange, I dark 
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orange, I red). Hydrogen bonds to a water molecule (red sphere) are indicated by 
dashed yellow lines [83]. 
 
The structure–activity relations done on GNF-2 showed that: The 4,6-pyrimidine substitution 
pattern is preferred over 2,4-substitution, and is strictly required to maintain cellular Bcr-Abl 
inhibitory activity by adopting the extended trans-conformation of the pyrimidine with the 4-
trifluoromethoxyaniline pointed toward the bottom of the pocket.   
The trifluoromethoxy group of GNF-2 can only be accommodated at the para position and it is 
an obligate; the aniline NH is required for the formation of a water-mediated hydrogen bond to 
the backbone carbonyls of A433 and E462; water-mediated hydrogen bonds between the 
carboxamide of GNF-2 which is pointed out toward the solvent exposed region and Abl confer 
enhanced inhibitory activity; and the extended compound conformation is required to fit the 
cylindrical binding cavity. 
Residues making contact with GNF-2 at the base of the pocket are L341 and A344 from E, I432 
from F, V468 from H, F493 from I, and I502 from I. The surface in the central part of the 
pocket is formed by A337 from E, C464 and P465 from the start of H, A433 from F, and 
V506 from I.  
Interactions at the mouth of the pocket are Y435 from F, E462 from the loop before H, and 
L510 at the end of I, which are few and caused by the flexibility and slightly weaker electron 
density of the benzamide part of GNF-2, and this clarifies the diverse range of functionalities that 
can be incorporated into this position (Figure 1.10 (b)). 
In addition, the compound did not exert inhibitory effect against other 40 kinases using cellular 
assays and 80 kinases using biochemical assays indicating the selective effect of GNF-2 [83, 84].  
 
GNF-2 could inhibit the phosphorylation of Bcr–Abl in all mutants except the three myristate-
site mutations (E505K, P465S and C464Y) that ablated the binding of Bcr–Abl to GNF-2 mainly 
for steric hindrance reason, and the ‘gatekeeper’ T315I mutation. 
Fortunately, it was reported recently that GNF-2 suppresses Imatinib-resistant Bcr-Abl mutants 
in cooperative manner when co-administered with imatinib, where the number of resistant clones 
that emerged as a result of continuous exposure to 1 µM imatinib was decreased by at least 90% 
when cells were treated for up to 21 days with 1 µM imatinib combined with 5 or 10 µM GNF-2 
(Figure 1.11 (a)) [85, 86]. 

 
Figure 1.11: (a) Effect of various concentrations of GNF-2, imatinib, or combinations of both on 
the number of emerging Ba/F3 Bcr-Abl -resistant clones [84], (b) IC50 for inhibition 
of wild-type, E505K and T315I Abl kinase activity by GNF-5, nilotinib or a 
combination of the two at an ATP concentration of 20 µM [84]. 
 
The N-hydroxyethyl carboxamide analogue of GNF-2, GNF-5 (Figure 1.8; (9)), is another 
example of this 4, 6-disubstituted pyrimidine series, with improved pharmacological profile. It 
was found that when GNF-5 is used in combination with the ATP-competitive inhibitors such as 
imatinib or nilotinib, it suppressed the emergence of resistance mutations in-vitro, displayed 
additive inhibitory activity in biochemical and cellular assays against T315I mutant Bcr-Abl and 
displayed in-vivo efficacy against this recalcitrant mutant and other mutants such E505K 
myristate mutant. Recently, Gray and his colleagues have shown that using a fixed GNF-5 
concentration of 1 µM and an ATP concentration of 20 µM, will decrease the IC50 values of 
nilotinib against T315I and wild-type enzyme by 4.7- and 9.6-fold, respectively, compared with 
those calculated in the absence of GNF-5 (Figure 1.11 (b)) [45, 84, 87]. 
The question is: How does binding in distant regions other than the ATP site influence kinase 
activity? How allosteric inhibitors can directly counteracts the effect of the mutation on the 
active-inactive kinase conformational equilibrium? And how these inhibitors could combine their 
effects? 
One possible explanation is that GNF-2/5 binding to the myristate pocket stabilizes the inactive 
form of the T315I mutant and that this binding makes I315 no longer impeding ATP competitive 
inhibitors from accessing to the hydrophobic pocket. 
Another recent research done by Gray and his colleagues using Hydrogen exchange (HX) mass 
spectrometry (MS) to study the conformational effects that result from binding of dasatinib and 

GNF-5, both individually and in combination, to wild-type Abl core and a T315I mutant version 
of Abl core shows that, GNF-5 binding alters the dynamics properties of the ATP site in both 
wild type and T315I forms of Abl. GNF-5 restores the conformational changes that are seen 
when dasatinib binds to wild-type Abl. Residues located at positions 325–343 in the ATP site 
were most influenced by GNF-5 binding and the T315I mutation did not alter the ability of GNF-
5 to elicit such changes. 
These results show that allosteric interactions play a significant role in the Abl kinase 
downregulation and that combining allosteric and ATP-competitive inhibitors can provide a 
mechanism by which synergistic interactions between these two sites could occur and overcome 
resistance to either agent alone [88-90]. 
 
1.7 Objectives: 
 
The major objective of this research is to explore the possibility of designing and synthesis of 
novel selective MBP inhibitors that will exert activity against Bcr-Abl expressing cells. 
Additional goal of the study will be to look for compounds that inhibit Imatinib resistant Bcr-Abl 
mutants.  
 
Specific goals are: 
A) Design series of novel MBP inhibitors based on GNF-2 and GNF-5 scaffolds. 
B) Synthesize, purify, and characterize those analogues. 
C) Assess for the ability of newly synthesized compounds to interfere in the auto-
phosphorylation Bcr-Abl and inhibit proliferation of Bcr-Abl transformed leukemia cells. 
D) Evaluate the ability of those new compounds to overcome the resistance emerging due to 
mutations at the Bcr-Abl kinase domain with special attention to the T315I gate-keeper 
mutation.  
 
1.8 Research Questions: 
 
Allosteric kinase inhibitors hold promise for revealing unique features of kinases that may not be 
apparent using conventional ATP-competitive inhibitors.  Recent works demonstrated promising 

lead compounds such as GNF-2/GNF-5 and derivatives that bind selectively to the MBP and 
inhibit cellular Bcr-Abl activity. The ability of these compounds to synergize with ATP-
competitive inhibitors to inhibit the growth of cells transformed with Bcr-Abl mutants when 
combined with preventing or delaying the emergence of resistance is perceived as should 
encourage this new therapeutic modality to be our promising target. Hence the research questions 
of the proposal in hand will be: 
 
Synthetic Question: 
Would it be possible to synthesize GNF-2 and GNF-5 analogues based on 4,6-
diaminopyrimidine derivatives that bind in higher affinity and improved selectivity to MBP in 
Bcr-Abl? 
 
Structure-Activity Question:  
Is it possible to explore 4,6-diaminopyrimidine scaffold to come up with new non-ATP 
competitors that  inhibit Bcr-Abl via binding to MBP?   
Would it be possible to overcome resistance rising due to mutations in the kinase domain by 
targeting the MBP in Bcr-Abl? 
 
1.9 Significance of Proposed Research: 
 
This research proposal constitutes a new potential approach to the treatment of CML and, if 
successful, could become complementary to the current methods of treatment mostly based on 
exploiting ATP-competitive inhibitors. It is hoped that such research would come out with novel 
molecular entities useful for studying several biomolecular systems in which myristoyl binding 
pocked is involved. It would be of value to define to what extent Abl and Bcr-Abl could be 
effectively inhibited by MBP binders that are remote from the active site of the kinases. Such 
effort will have implications to studies and plans for inhibitor development in other kinase 
studies. 
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Chapter Two 
 
 
 
Experimental part 
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2. Experimental part: 
 
2.1  Materials: 
 
Chemicals: 4,6-dichloropyrimidine, p-trifluoromethoxyaniline, 4-fluoroaniline, 3,4-dimethoxy-
benzoic acid, 4-ethylbenzoic acid, 1-naphthoic acid, benzoyl chloride, oxalyl chloride, methyl 
sulfonyl chloride (mesyl chloride), P-toluene sulfonyl chloride (Tosyl chloride), 4-
trifluoromethylbenzoic acid, biphenyl-4-carboxylic acid, benzofuran-2-carboxylic acid, 6-
methoxybenzofuran-2-carboxylic acid, piperazine,  phenyl-piperazine, piperazine-1-carboxylic 
acid tert-butyl ester (BOC-pz), 2-(1-piperazinyl) pyrimidine, 1-(4-pyridyl)piperazine, 1-(pyridin-
2-yl)-piperazine, 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine, 2-bromo-1-(2,3-dihydro-
benzo{1,4}dioxin-6-yl)-ethanone, dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide 
(NHS), sodium sulfate (Na2SO4), diisopropylethylamine (DIPEA), potassiumcarbonate (K2CO3), 
calcium chloride (CaCl2),  potassiumbromide (KBr), dimethylformamimde (DMF), 
dichloromethane (DCM), ethyl acetate (EA), triethylamine (TEA), methanol (MeOH), ethanol 
(EtOH), hexane, isopropanol, chloroform (CHCl3) and  hydrochloric acid (HCl)  were purchased 
from ACROS Chemicals Ltd, and were used without further purification.  
Silica gel (Silica gel 60 (0.040-0.063 mm)), thin layer chromatography (TLC) (TLC Silica gel 60 
F254) sheets were all purchased from Merck Ltd. 
Deuterated solvents: D2O, CDCl3, DMSO-d6 were purchased from ACROS Chemicals Ltd.  
Commercially available starting materials including aromatic carboxylic acids [3,4-dimethoxy-
benzoic acid (58), 4-trifluoromethylbenzoic acid (59), 4-ethylbenzoic acid (60), 4-phenyl-
benzoic acid (61) and 1-naphthoic acid (62)] were all purchased and used with no further 
purification. 
 
2.2 Instrumentation: 
 
2.2.1 Nuclear magnetic resonance (
1
H-, 
13
C-, COSY & HMBC NMR): Data were collected 
using Varian Unity Inova 500 MHz spectrometer equipped with a 5-mm switchable probe and 
data were processed using the VNMR software. 

1H-NMR chemical shifts are reported in parts per million (ppm, ) downfield from 
tetramethylsilane (TMS). Spin multiplicities are described as s (singlet), brs (broad singlet), t 
(triplet), q (quartet), and m (multiplet). 
 
2.2.2 Fourier transform infrared spectroscopy (FTIR): All infrared spectra were obtained 
from a KBr matrix (4000–400 cm-1) using a Perkin-Elmer spectrum 100, FT-IR spectrometer.  
 
2.2.3 Electrospray ionization mass spectrometry (ESIMS): Was performed using a Thermo 
Quest Finnigan LCQ-Duo in the positive ion mode.  
Elution was in a mixture of 49:49:2 water/methanol/acetic acid at a flow rate of 15 L/minute. 
 
2.3 Synthetic Chemistry: 
 
2.3.1 Synthesis of GNF-2 and GNF-5 analogues: 
 
2.3.1.1 Synthesis of (6-chloro-pyrimidin-4-yl)-(4-trifluoromethoxy-phenyl)-amine (13): 
 
In a 25 ml round bottom flask (1.0 g, 6.7 mmol) of 4,6-dichloropyrimidine (10) and (1.19 g, 6.7 
mmol) of p-trifluoromethoxyaniline (11) were dissolved in 15 ml ethanol and 2 ml DIPEA 
(diisopropylethylamine), then the mixture was refluxed for 2 h and the reaction progress was 
followed using TLC (CHCl3). When the reaction was completed ethanol was evaporated, and the 
crude product was purified by column chromatography using CHCl3 to give 1.55 g of white 
fluffy powder. TLC (CHCl3), Rf = 5.8/8.2 = 0.; yield: 1.55 g (80%); 1H-NMR 300 MHz 
(CDCl3,  (ppm) 6.60-6.70 (s, 1H), 6.90-7.00 (s, 1N-H amide), 7.30-7.35 (d, 2H), 7.35-7.45 (d, 
2H), 8.45-8.55 (s, 1H). 
 
2.3.1.2 Synthesis of [6-(4-phenyl-piperazin-1-yl)-pyrimidin-4-yl]-(4-trifluoromethoxy-
phenyl)-amine {MYJ-1 (20)}: 
 
In a 25 ml round bottom flask (0.5 g, 1.7 mmol) of (6-chloro-pyrimidin-4-yl)(4-
trifluoromethoxy-phenyl)-amine (13) and (0.28 g, 0.26 ml, 1.7 mmol) of phenylpiperazine (36) 

and (0.24 g, 1.7 mmol) of K2CO3 were dissolved in 10 ml DMF, the reaction mixture was 
refluxed at 100 °C for 12 h and the completion of the reaction was indicated by TLC (CHCl3).  
When the reaction was completed the DMF was evaporated to dryness, and the crude product 
was purified by column chromatography using CHCl3:hexane (50:50; v:v) to give 0.37 g 
brownish powder. TLC (CHCl3), Rf = 5.1/7.8 = 0.65; yield: 0.37g (52%); 
1H-NMR 300 MHz 
(CDCl3,  (ppm) 3.20-3.30 (m, 4H), 3.55-3.75 (m, 4H), 5.80-5.90 (d, 1H), 6.85-6.95 (m, 4H), 
7.20-7.30 (m, 5H), 7.24 (s, 1H amine), 8.25-8.35 (s, 1H); FT-IR (KBr) (cm-1): 3310.5 (N-H) 
stretching, 3072.9 Ar-H (C-H stretch), 2925.5, 2817.1 CH2, CH3 (C-H stretch), 1601.2, 1575.8 & 
1496.8 (C=C) aromatic & (C=N) stretching, 1440.5, 1409.1, 1382.8 & 1332.8 (C-H) bending, 
873.5, 690.2, 661.3 & 562.3 Ar-H (H2C=CH2 bending). 
 
2.3.1.3 Synthesis of 4-[6-(4-trifluoromethoxyphenylamino)-pyrimidin-4-yl]-piperazine-1-
carboxylic acid tert-butyl ester {MYJ-2 (16)}: 
 
In a 25 ml round bottom flask (0.5 g, 1.7 mmol) of (6-chloro-pyrimidin-4-yl)(4-
trifluoromethoxy-phenyl)-amine (13) and (0.32 g, 1.7 mmol) of piperazine-1-carboxylic acid 
tert-butyl ester (15) and (0.24 g, 1.7 mmol) of K2CO3 were dissolved in 10 ml DMF, the reaction 
mixture was refluxed at 100 °C for 12 h and the completion of the reaction was indicated by TLC 
(CHCl3). When the reaction was completed the DMF was evaporated to dryness the crude 
product was purified by column chromatography using CHCl3:hexane (50: 50; v:v) to give 0.44 
g yellowish powder. TLC (CHCl3), Rf = 4.6/7.9 = 0.58; yield: 0.44 g (58%); 
1H-NMR 300 MHz 
(CDCl3,  ppm) 1.40-1.50 (s, 9H), 3.45-3.55 (dd, 8H), 5.80-5.85 (s, 1H), 7.20-7.30 (d, 2H), 7.25-
7.35 (d, 2H), 7.50-7.70 (s, 1H), 8.20-8.30 (s, 1 N-H amine); FT-IR (KBr) (cm-1): 3341 (N-H) 
stretching, 1590.4 (C=O), 1365.5 (C-H) bending, 792.1, 661.4 Ar-H (H2C=CH2 bending). 
 
2.3.1.4 Synthesis of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-trifluoromethoxy-phenyl)-amine 
acidic salt (18): 
 
In a 25 ml round bottom flask (0.5 g, 1.7 mmol) of (6-chloro-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine (13) and (0.32 g, 1.7 mmol) of piperazine-1-carboxylic acid 
tert-butyl ester (15) and (0.24 g, 1.7 mmol) of K2CO3 were dissolved in 10 ml DMF, the reaction 
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mixture was refluxed at 100 °C for 12 h and the completion of the reaction was indicated by TLC 
(CHCl3). When the reaction was completed the DMF was evaporated to dryness the crude 
product was purified by column chromatography using CHCl3:hexane (50:50; v:v) to give 0.44 g 
yellowish powder. 
The obtained pure powder {MYJ-2 (16)}, was then dissolved in (15 ml) EtOH and acidified by 
0.5 ml conc HCl and stirred for 1 h. Then the mixture was allowed to cool in ice-bath overnight, 
and the precipitate was filtered off. The precipitate was washed with additional 10 ml ethanol 
and filtrates were collected and evaporated to dryness to give a white precipitate of 
corresponding (6-piperazin-1-yl-pyrimidin-4-yl)-(4-trifluoromethoxy-phenyl)-amine 
hydrochloride salt (18). TLC (EA: MeOH (90:10; v:v)), Rf = 1.5/7.9 = 0.19; yield: 0.39 g (75%); 
1H-NMR 300 MHz (DMSO-d6),  (ppm), 3.15-3.20 (s, 4H), 3.85-3.90 (s, 4H), 6.10 (s, 1H), 7.30-
7.40 (dd, 2H), 7.55-7.65 (dd, 2H), 8.40-8.45 (s, 1H), 9.50-9.80 (s, 1H amine), 10.35-10.75 (s, 1H 
amine). 
 
2.3.1.5 Preparation of aromatic acyl halides: 
 
Under calcium chloride tube, aromatic fatty acid was dissolved in dry DCM (20 ml) and cooled 
in ice-bath to -5 ºC. While stirring at r.t, two equivalents of oxalyl chloride were added. Gas 
bubbles were evolved to indicate the release of gaseous CO2 and HCl. The progress of the 
reaction was followed by TLC (CHCl3 or EA). When the reaction was over, the volatiles were 
removed to dryness under reduced pressure leaving the desired product.  
 
2.3.1.5.1  Benzoyl chloride (21):  
 
TLC (CHCl3), Rf = 6.8/8.0 = 0.85; commercially available; 
1H-NMR (CDCl3,  ppm): 7.45-7.50 
(m, 2H), 7.55-7.60 (m, 1H), 7.95-7.80 (d, 2H). 
 
2.3.1.5.2  3, 4-Dimethoxybenzoyl chloride (22):  
 
TLC (EA), Rf = 4.9/7.8 = 0.63; yellowish solid; yield: 1.057 g (96%); 1H-NMR (CDCl3,  ppm): 
3.75 (q, 6H), 6.77 (d, 1H), 7.48 (d, 1H), 7.49 (d, 1H). 
	
 
2.3.1.5.3  4-Trifluoromethylbenzoyl chloride (23):  
 
TLC (EA), Rf = 3.4/7.8 = 0.44; yellowish solid; yield: 0.213 g (97%); 1H-NMR (CDCl3,  ppm): 
7.65 (d, 2H), 8.01 (d, 2H). 
 
2.3.1.5.4  4-Ethylbenzoyl chloride (24):  
 
TLC (CHCl3), Rf = 6.6/8.0 = 0.83; yellowish liquid; yield: 0.321 g (95%); 
1H-NMR (CDCl3,  
ppm): 1.24 (t, 3H), 2.59 (q, 2H), 7.33 (d, 2H), 8.02 (d, 2H).  
 
2.3.1.5.5  4-Phenylbenzoyl chloride (25):  
 
TLC (CHCl3), Rf = 6.7/8.0 = 0.84; yellowish-white solid; yield: 1.057 g (96%); 
1H-NMR 
(CDCl3,  ppm): 7.22 (d, 1H), 7.29 (d, 2H), 7.50 (d, 2H), 7.66 (d, 2H), 8.12 (d, 2H).  
 
2.3.1.5.6  1-Naphthoyl chloride (54):  
 
TLC (CHCl3), Rf = 6.5/7.9 = 0.82; green-white solid; yield: 1.169 g (96%)
 
; 
1H-NMR (CDCl3,  
ppm): 7.50 (d, 1H), 7.57 (d, 1H), 7.65 (d, 1H), 7.86 (d, 1H), 8.04 (d, 1H), 8.51 (d, 1H), 8.74 (d, 
1H). 
 
2.3.1.6 Synthesis of (3,4-dimethoxy-phenyl)-{4-[6-(4-trifluoromethoxy-phenylamino)-
pyrimidin-4-yl]-piperazin-1-yl}-methanone {MYJ-16 (28)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (76.9 mg, 0.38 mmol) of 3,4-dimethoxy-benzoyl 
chloride (22) was then added to the reaction mixture and stirred for 48 h. The completion of the 
reaction was indicated by TLC (EA), when the reaction was completed the DMF was evaporated 
to dryness and crude product was extracted by EA against distilled basic water. The organic 
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phase was dried over Na2SO4 and the solvent was removed under reduced pressure. The desired 
product was purified by column chromatography using CHCl3:hexane (70:30; v:v)), to give 86.7 
mg off-white powder. 
TLC (EA), Rf = 4.6/8.4 = 0.55; yield: 0.087 g (44.9%); 1H-NMR 300 MHz (DMSO-d6),  (ppm) 
3.50-3.60 (s, 8H), 3.75-3.85 (d, 6H), 5.95-6.00 (s, 1H), 7.00-7.02 (d, 2H), 7.01-7.03 (s, 1H), 
7.20-7.30 (d, 2H), 7.65-7.75 (d, 2H), 8.20-8.25 (s, 1H), 9.20-9.30 (s, 1 N-H amine); 13C{1H}-
NMR (DMSO-d6,  ppm), 169.92, 162.69, 161.38, 157.96, 150.55, 149.04, 142.87, 140.80, 
128.40, 122.25, 120.86, 120.74, 111.71, 85.48, 56.21. 
The 1H-1H correlation spectroscopy (COSY) NMR spectral revealed only two cross-peaks: H (3, 
3?)/H (4, 4?) and H (4, 4?)/H (3, 3?).  
HMBC spectrum showed many informative correlations, such as: H 7.65-7.75 (2H, d, H-3, 3`) to 
C(2), C(4), C(4`) and C(5); H 7.20-7.30 (2H, d, H-4, 4`) to C(2), C(3), C(3`) and C(5); H 9.20-
9.30 (1H, s, H-6) to C(4), C(4?), C(7) and C(8); H 5.95-6.00 (1H, s, H-8) to C(6), C(7) and 
C(9); H 8.20-8.25 (1H, s, H-10) to C(7) and C(9); H 3.50-3.60 (8H, s, H-11, 11`) to C(12) and 
C(12`); H 3.50-3.60 (8H, s, H-12, 12`) to C(11) and C(11`); H 7.01-7.03 (1H, s, H-15) to C(13), 
C(14), C(16), C(17) and C(18); H 7.00-7.02 (2H, d, H-18) to C(14), C(16), C(17) and C(19); H 
7.00-7.02 (2H, d, H-19) to C(14), C(15), C(17) and C(18) (Figure 2.1, Table 2.1). 
FT-IR (KBr) (cm-1): 3322.6 & 3197.4 (N-H) stretching, 3012.5 Ar-H (C-H stretch), 2965 & 
2860.4 CH2, CH3 (C-H stretch), 1602 (C=O), 1510.5 (C=C) aromatic & (C=N) stretching, 1434, 
1381.4, 1333.2 & 1301 (C-H) bending, 856.7, 701.5 & 653.1 Ar-H (H2C=CH2 bending). 
MS (ESI) m/z calculated for C24H24F3N5O4 503.47, found 504.11 (M +H)
 +. 
 
 
 
Figure 2.1: Chemical structure of 28. 
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Table 2.1: NMR data of compound 28:  
 
Positions 1H-NMR (ppm) 13C-NMR (ppm) 1H-1H COSY 1H-13C HMBC 
1 - 122.25 (C) -  
2 -  140.80 (C) -  
3, 3? 7.65-7.75 (d, 2H) 120.86 (CH) 4, 4? 
C(2), 
C(4),C(4?), C(5) 
4, 4? 7.20-7.30 (d, 2H) 120.86 (CH) 3, 3? 
C(2), C(3), 
C(3?), C(5) 
5 - 142.78 (C) -  
6 9.20-9.30 (s, 1H) - - 
C(4), C(4`), C(7), 
C(8) 
7 - 161.38 (C) -  
8 5.95-6.00 (s, 1H) 85.48 (CH) - C(6), C(7), C(9) 
9 - 162.69 (C) -  
10 8.20-8.25 (s, 1H) 157.96 (CH) - C(7), C(9) 
11, 11? 3.50-3.60 (s, 8H) 56.21 (CH2) - C(12), C(12?) 
12, 12? 3.50-3.60 (s, 8H) 56.21 (CH2) - C (11), C(11?) 
13 - 169.92 (C) -  
14 - 128.40 (C) -  
15 7.01-7.03 (s, 1H) 111.71 (CH) - 
C(13), C(14), 
C(16), C(17), 
C(18) 
16 - 150.55 (C) -  
17 - 150.55 (C) -  
18 7.00-7.02 (d, 2H) 111.71 (CH) - 
C(14), C(16), 
C(17), C(19)  
19 7.00-7.02 (d, 2H) 120.74 (CH) - 
C(14), C(15),  
C(17), C(18) 
20, 20? 3.75-3.85 (d, 6H) 149.04 (CH3) -  
 
 
2.3.1.7 Synthesis of 1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-2-{4-[6-(4-trifluoromethoxy-
phenylamino)-pyrimidin-4-yl]-piperazin-1-yl}-ethanone {MYJ-17 (29)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (97.7 mg, 0.38 mmol) of 2-bromo-1-(2,3-dihydro-
benzo[1,4]dioxin-6-yl)-ethanone (26) was then added to the reaction mixture and stirred for 6 h. 
The completion of the reaction was indicated by TLC (CHCl3), when the reaction was completed 
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the DMF was evaporated to dryness and the crude product was extracted by CHCl3 against 
distilled water. The organic phase was dried over Na2SO4 and the solvent was removed under 
reduced pressure. The desired product was purified by column chromatography using 
CHCl3:hexane (50:50; v:v) to give 80 mg of yellow to brown powder. TLC (CHCl3), Rf = 
4.2/8.4 = 0.5; yield: 0.08 g (41%); 1H-NMR 300 MHz (DMSO-d6),  (ppm) 3.05-3.10 (s, 2H), 
3.45 (t, 2H), 3.61 (t, 2H), 3.71 (t, 2H), 3.83 (t, 2H), 4.30-4.40 (dd, 4H), 5.85 (s, 1H), 6.95-7.00 
(d, 1H), 7.10 (s, 1H amine), 7.20-7.25 (d, 2H), 7.28 (s, 1H), 7.35-7.40 (d,2H), 7.50 (d, 1H), 8.25-
8.30 (s, 1H); FT-IR (KBr) (cm-1): 3359.9 (N-H) stretching, 2923.9 CH2, CH3 (C-H stretch), 
1588.4 (C=O), 1508.6 (C=C) aromatic & (C=N) stretching, 1379.3, 1260.2 (C-H) bending, 
1103.6, 800 & 638.2 Ar-H (H2C=CH2 bending). 
 
2.3.1.8 Synthesis of phenyl-{4-[6-(4-trifluoromethoxy-phenylamino)-pyrimidin-4-yl]-
piperazin-1-yl}-methanone {MYJ-18 (30)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (53.4 mg, 0.044 ml, 0.38 mmol) of benzoyl chloride 
(21) was then added to the reaction mixture and stirred for 48 h. The completion of the reaction 
was indicated by TLC (EA), when the reaction was completed the DMF was evaporated to 
dryness and crude product was extracted by EA against distilled basic water. The organic phase 
was dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product 
was purified by column chromatography using CHCl3:hexane (50:50; v:v) to give compound 30 
with a little impurity, which was followed by re-crystalization using isopropanol as solvent to 
afford 0.0884 g off-white powder of desired product. TLC (EA), Rf = 4.2/7.5 = 0.56; yield: 
0.0884 g (52%); 1H-NMR 300 MHz (CDCl3)  (ppm) 3.65-3.75 (d, 8H), 5.85-5.90 (s, 1H), 7.25 
(d, 2H), 7.36 (d, 2H), 7.55-7.60 (t, 1H), 7.46 (m, 4H), 8.25-8.30 (s, 1H), 8.70-8.75 (s, 1H amine); 
FT-IR (KBr) (cm-1): 3332.0 & 3231.1 (N-H) stretching, 2964.3 & 2853.9 CH2, CH3 (C-H 
stretch), 1600.5 (C=O), 1509.0 (C=C) aromatic & (C=N) stretching, 1453.8 & 1361.6 (C-H) 
bending, 977.2, 926.0, 804.0 & 709.1 Ar-H (H2C=CH2 bending); MS (ESI) m/z calculated for 
C22H20F3N5O2 443.42, found 444.47 (M +H)
 +. 
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2.3.1.9 Synthesis of {4-[6-(4-trifluoromethoxy-phenylamino)-pyrimidin-4-yl]-piperazin-1-
yl}-(4-trifluoromethyl-phenyl)-methanone {MYJ-19 (31)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (79.3 mg, 0.38 mmol) of 4-trifluoromethylbenzoyl 
chloride (23) was then added to the reaction mixture and stirred for 6 h. The completion of the 
reaction was indicated by TLC (EA), when the reaction was completed the DMF was evaporated 
to dryness and crude product was extracted by EA against distilled water. The organic phase was 
dried over Na2SO4 and the solvent was removed under reduced pressure. The desired product 
was purified by column chromatography using CHCl3:hexane (50:50; v:v) to give 0.128 g 
brownish powder. TLC (EA), Rf = 4.7/7.5 = 0.63; yield: 0.128 g (65%); 1H-NMR 300 MHz 
(CDCl3)  (ppm) 3.65-3.70 (t, 8H), 5.85-5.90 (s, 1H), 7.10 (s, 1H amine), 7.23 (d, 2H), 7.35 (d, 
2H), 7.56 (d, 2H), 7.72 (d, 2H), 8.25-8.30 (s, 1H); FT-IR (KBr) (cm-1): 3238.5 & 3345.5 (N-H) 
stretching, 2852.7 CH2, CH3 (C-H stretch), 1629.7 (C=O), 1587, 1509 (C=C) aromatic & (C=N) 
stretching, 1440.5, 1408.3 & 1384 (C-H) bending, 1001.7, 847.7 & 765.8 Ar-H (H2C=CH2 
bending); MS (ESI) m/z calculated for C23H19F6N5O2 511.42, found 512.16 (M +H)
 +. 
 
2.3.1.10 Synthesis of [6-(4-methanesulfonyl-piperazin-1-yl)-pyrimidin-4-yl]-(4-
trifluoromethoxy-phenyl)-amine {MYJ-20 (32)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (43.9 mg, 0.38 mmol) of methyl sulfonyl chloride 
(mesyl chloride) (27) was then added to the reaction mixture and stirred for 24 h. The completion 
of the reaction was indicated by TLC (EA), when the reaction was completed the DMF was 
evaporated to dryness and crude product was extracted by EA against distilled water. The 
organic phase was dried over Na2SO4 and the solvent was removed under reduced pressure. The 
desired product was purified by column chromatography using CHCl3 to give 0.144 g off-white 
to beige powder. TLC (EA), Rf = 4.7/7.6 = 0.62; yield: 0.144 g (91%); 1H-NMR 300 MHz 
(DMSO-d6),  (ppm), 2.85-2.95 (s, 3H), 3.20-3.30 (t, 4H), 3.60-3.70 (t, 4H), 6.00-6.05 (s, 1H), 
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7.20-7.30 (d, 2H), 7.65-7.75 (d, 2H), 8.20-8.25 (s, 1H), 9.25-9.35 (s, 1 N-H amine); 13C{1H}-
NMR ((DMSO-d6,  ppm), 165.01, 145.11, 142.67, 125.06, 124.12, 123.99, 123.68, 122.59, 
122.15, 88.51, 48.83, 47.78, 37.45; FT-IR (KBr) (cm-1): 2964.7 Ar-H (C-H stretch), 1585, 
1504.5 (C=C) aromatic & (C=N) stretching, 1457.8, 1360.9 (C-H) bending, 796, 694.3 & 634.9 
Ar-H (H2C=CH2 bending); MS (ESI) m/z calculated for C16H18F3N5O3S 417.41, found 418.15 
(M +H) +. 
 
2.3.1.11 Synthesis of   biphenyl-4-yl-{4-[6-(4-trifluoromethoxy-phenylamino)-pyrimidin-4-
yl]-piperazin-1-yl}-methanone {MYJ-21 (33)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (83.1 mg, 0.38 mmol) of biphenyl-4-carbonyl 
chloride (25) was then added to the reaction mixture and stirred for 24 h. The completion of the 
reaction was indicated by TLC (EA), when the reaction was completed the DMF was evaporated 
to dryness and crude product was extracted by EA against distilled water. The organic phase was 
dried over Na2SO4 and the solvent was removed under reduced pressure. The desired product 
was purified by column chromatography using CHCl3 to give 0.186 g of beige powder. TLC 
(EA), Rf = 4.4/7.6 = 0.58; yield: 0.186 g (93%); 1H-NMR 300 MHz (DMSO-d6),  (ppm), 3.60-
3.65 (d, 8H), 5.95-6.00 (s, 1H), 7.20-7.30 (d, 2H), 7.40-7.45 (t, 1H), 7.50-7.55 (t, 2H), 7.55-7.60 
(d, 2H), 7.70-7.75 (m, 4H), 7.75-7.80 (d,2H), 8.20-8.25 (s, 1H), 9.25-9.35 (s, 1 N-H amine); FT-
IR (KBr) (cm-1): 3330.5, 3230.7 (N-H) stretching, 2964.3 CH2, CH3 (C-H stretch), 1617 (C=O), 
1509 (C=C) aromatic & (C=N) stretching, 1425.6 & 1362.1 (C-H) bending, 977.5, 849.5 & 
695.9 Ar-H (H2C=CH2 bending). 
 
2.3.1.12 Synthesis of   (4-ethyl-phenyl)-{4-[6-(4-trifluoromethoxy-phenylamino)-pyrimidin-
4-yl]-piperazin-1-yl}-methanone {MYJ-23 (35)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (64.1 mg, 0.056 ml, 0.38 mmol) of 4-ethylbenzoyl 
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chloride (24) was then added to the reaction mixture and stirred for 24 h. The completion of the 
reaction was indicated by TLC (EA), when the reaction was completed the DMF was evaporated 
to dryness and crude product was extracted by EA against distilled water. The organic phase was 
dried over Na2SO4 and the solvent was removed under reduced pressure. The desired product 
was purified by column chromatography using CHCl3: EA (80:20; v:v) to give 0.172 g as off-
white powder. TLC (EA), Rf = 4.6/7.7 = 0.6; yield: 0.172 g (95%); 1H-NMR 300 MHz (DMSO-
d6),  (ppm) 1.15 (t, 3H), 2.60-2.65 (q, 2H), 3.55 (s, 8H), 5.94 (s, 1H), 7.25-7.30 (dd, 4H), 7.30-
7.35 (dd, 2H), 7.65-7.70 (dd, 2H), 8.20-8.25 (s, 1H), 9.30-9.35 (s, 1 N-H amine); FT-IR (KBr) 
(cm-1): 3330.5 &  3231 (N-H) stretching, 2965.2 CH2, CH3 (C-H stretch), 1683.7, 1617.5 (C=O), 
1508 (C=C) aromatic & (C=N) stretching, 1427, 1361.6 (C-H) bending, 693.9, 637.4, 606.8 & 
509.9 Ar-H (H2C=CH2 bending). 
 
2.3.1.13 Synthesis of   naphthalen-1-yl-{4-[6-(4-trifluoromethoxy-phenylamino)-pyrimidin-
4-yl]-piperazin-1-yl}-methanone {MYJ-25 (57)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (73.1 mg, 0.38 mmol) of 1-naphthoyl chloride (54) 
was then added to the reaction mixture and stirred for 24 h. The completion of the reaction was 
indicated by TLC (EA), when the reaction was completed the DMF was evaporated to dryness 
and crude product was extracted by EA against distilled water. The organic phase was dried over 
Na2SO4 and the solvent was removed under reduced pressure. The desired product was purified 
by column chromatography using CHCl3:EA (70:30; v:v), and finally afforded by re-
crystallization using isopropanol as eluent to give 0.122 g of brownish desired precipitate. TLC 
(EA), Rf = 4.8/7.8 = 0.62; yield: 0.122 g (64.9%); 1H-NMR 300 MHz (DMSO-d6),  (ppm), 
3.20-3.38 (t, 4H), 3.70-3.90 (t, 4H), 5.90-5.95 (s, 1H), 7.20-7.25 (dd, 2H), 7.45-7.55 (dd, 2H), 
7.55-7.60 (dd, 2H), 7.65-7.70 (dd, 2H), 7.80 (m, 1H), 7.95-7.99 (d,1H), 7.99-8.10 (d,1H), 8.20-
8.25 (s, 1H), 9.25-9.30 (s, 1 N-H amine); FT-IR (KBr) (cm-1): 3328.3, 3236.8 & 3198 (N-H) 
stretching, 3133.1 Ar-H (C-H stretch), 3012.8, 2901.5 & 2855.2 CH2, CH3 (C-H stretch), 1805.7, 
1633.5 & 1620.6 (C=O), 1589.9 & 1507.9 (C=C) aromatic & (C=N) stretching, 1412.7, 1393.3 
& 1361.3 (C-H) bending, 949.6, 871.1 & 733.2 Ar-H (H2C=CH2 bending). 
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2.3.1.14 Synthesis of {6-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-pyrimidin-4-yl}-(4-
trifluoromethoxy-phenyl)-amine {MYJ-26 (56)}: 
 
In a 25 ml round bottom flask (200 mg, 0.38 mmol) of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-
trifluoromethoxy-phenyl)-amine acidic salt (18), and 7.0 eq TEA (0.37 ml, 2.66 mmol) were 
dissolved in 10 ml DMF and cooled to 0 °C. (72.4 mg, 0.38 mmol) of P-toluene sulfonyl chloride 
(tosyl chloride) (55) was then added to the reaction mixture and stirred for 24 h. The completion 
of the reaction was indicated by TLC (EA), when the reaction was completed the DMF was 
evaporated to dryness and crude product was extracted by EA against distilled water. The 
organic phase was dried over Na2SO4 and the solvent was removed under reduced pressure. The 
desired product was finally obtained by re-crystallization using isopropanol as solvent to give 
0.150 g of brownish solid. TLC (EA), Rf = 5.1/8.0 = 0.64; yield: 0.150 g (80.2%); 1H-NMR 300 
MHz (DMSO-d6),  (ppm), 2.90-2.95 (t, 4H), 3.55-3.60 (t, 4H), 5.90-5.95 (s, 1H), 7.20-7.25 (d, 
2H), 7.40-7.45 (d, 2H),  7.60-7.65 (m, 5H), 8.15-8.20 (s, 1H), 9.25-9.35 (s, 1 N-H amine); FT-IR 
(KBr) (cm-1): 3375, 3231 & 3192 (N-H) stretching, 3125 Ar-H (C-H stretch), 2968, 2846 & 
2738.4 CH2, CH3 (C-H stretch), 1625, 1592 & 1510.1 (C=C) aromatic & (C=N) stretching, 1446, 
1428& 1328.8(C-H) bending, 917.3, 897.2, 706.4 & 668.4 Ar-H (H2C=CH2 bending). 
 
2.3.1.15 Synthesis of (6-chloro-pyrimidin-4-yl)-(4-fluoro-phenyl)-amine (14): 
 
In a 25 ml round bottom flask (1.0 g, 6.7 mmol) of 4,6-dichloropyrimidine (10) and (0.64 ml, 6.7 
mmol) of 4-fluoroaniline (12) were dissolved in 15 ml ethanol and 2 ml DIPEA 
(diisopropylethylamine), then the mixture was refluxed for 2 h and the reaction progress was 
followed using TLC (CHCl3). When the reaction was completed ethanol was evaporated under 
reduced pressure, and the crude solid was washed with additional 10 ml ethanol and evaporated 
to dryness using suction filtration to give a white solid of corresponding amine. TLC (CHCl3), Rf 
= 5.9/8.1 = 0.73; yield: 1.27 g (85%); 1H-NMR 300 MHz (DMSO-d6),  (ppm) 6.75-6.80 (s, 1H), 
7.20 (dd, 2H), 7.63 (dd, 2H), 8.45-8.50 (s, 1H), 9.90-9.95(s, 1H amine). 
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2.3.1.16 Synthesis of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-fluoro-phenyl)-amine acidic salt 
(19): 
 
In a 25 ml round bottom flask (0.5 g, 2.24 mmol) of (6-chloro-pyrimidin-4-yl)-(4-fluoro-phenyl)-
amine (14) and (0.42 g,2.24 mmol) of piperazine-1-carboxylic acid tert-butyl ester (15) and (0.31 
g, 2.24 mmol) of K2CO3 were dissolved in 10 ml DMF, the reaction mixture was refluxed at 100 
°C for 12 h and the completion of the reaction was indicated by TLC (CHCl3). 
When the reaction was completed the DMF was evaporated to dryness and the crude product was 
purified by column chromatography using CHCl3:hexane (50:50; v:v) to give 0.40 g of yellowish 
powder of 4-[6-(4-fluoro-phenylamino)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl 
ester (17). 
The obtained pure powder was then dissolved in (15 ml) EtOH and acidified by 0.5 ml conc HCl 
and stirred for 1 h.  The mixture was then allowed to cool in ice-bath overnight (refrigerator), 
and the precipitate was filtered off. The precipitate was washed with additional 10 ml ethanol 
and filtrates were collected and evaporated to dryness to give a white solid. 
TLC (EA: MeOH (90:10; v:v)), Rf = 1.6/8.1 = 0.2; yield: 0.39 g (80%); 1H-NMR 300 MHz 
(DMSO-d6),  (ppm) 3.15-3.20 (s, 4H), 3.85-3.90 (s, 4H), 6.10 (s, 1H), 7.25-7.30 (dd, 2H), 7.45-
7.50 (dd, 2H), 8.40-8.45 (s, 1H), 9.50-9.80 (s, 1H amine), 10.35-10.75 (s, 1H amine). 
 
2.3.1.17 Synthesis of (3,4-dimethoxy-phenyl)-{4-[6-(4-fluoro-phenylamino)-pyrimidin-4-yl]-
piperazin-1-yl}-methanone {MYJ-22 (34)}: 
 
In a 25 ml round bottom flask (200 mg, 0.44 mmol) (6-piperazin-1-yl-pyrimidin-4-yl)-(4-fluoro-
phenyl)-amine acidic salt (19), and 7.0 eq TEA (0.43 ml, 3.07 mmol) were dissolved in 10 ml 
DMF and cooled to 0 °C. (88.3 mg, 0.44 mmol) of 3,4-dimethoxy-benzoyl chloride (22) was 
then added to the reaction mixture and stirred for 48 h.  The completion of the reaction was 
indicated by TLC (EA), when the reaction was completed the DMF was evaporated to dryness 
and crude product was extracted by EA against distilled basic water. The organic phase was 
dried over Na2SO4 and the solvent was removed under reduced pressure. The desired product 
was purified by column chromatography using CHCl3:EA (80:20; v:v), to give 87 mg brownish 
powder.  
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TLC (EA), Rf = 2.0/7.6 = 0.26; yield: 0.087 g (45%); 1H-NMR 300 MHz (DMSO-d6),  (ppm) 
3.50-3.60 (s, 8H), 3.75-3.80 (d, 6H), 5.85-5.90 (s, 1H), 6.95-7.00 (d, 3H), 7.05-7.10 (t, 2H), 7.50-
7.55 (m, 2H), 8.15-8.20 (s, 1H), 9.10-9.15 (s, 1 N-H amine); FT-IR (KBr) (cm-1): 3746.9, 3672.1 
& 3650.1 (N-H) stretching, 2964.2 Ar-H (C-H stretch), 1594.7 (C=O), 1508 (C=C) aromatic & 
(C=N) stretching, 1432.8 (C-H) bending, 876.7, 702.2 & 616.4 Ar-H (H2C=CH2 bending). 
 
2.3.2 Synthesis of piperazine symmetrical analogues: 
 
2.3.2.1 Synthesis of 1,4-Piperazine, bis {(6-Pyrimidin)-(4-trifluoromethoxy-phenyl)-amine}  
{MYJ-24 (38)}:  
 
In a 25 ml round bottom flask (100 mg, 1.16 mmol) of piperazine pure (37) and 2.0 eq (6-chloro-
pyrimidin-4-yl)-(4-trifluoromethoxy-phenyl)-amine (13) (0.672 mg, 2.32 mmol) and (0.321 g, 
2.32 mmol) of K2CO3 were dissolved in 10 ml DMF, the reaction mixture was refluxed at 100 °C 
for 12 h and the completion of the reaction was indicated by TLC (EA). When the reaction was 
completed the DMF was evaporated to dryness and crude product was extracted by EA against 
distilled water. The organic phase was dried over Na2SO4 and the solvent was removed under 
reduced pressure. The desired product was purified by column chromatography using CHCl3 to 
give 309 mg brownish powder. TLC (EA), Rf = 3.5/7.6 = 0.46; yield: 0.309 g (45%); 1H-NMR 
300 MHz (DMSO-d6),  (ppm) 3.66 (s, 8H), 5.98 (s, 2H), 7.25 (d, 4H), 7.70 (d, 4H), 8.23 (s, 
2H), 9.30 (s, 2H); 13C{1H}-NMR ((DMSO-d6,  ppm), 164.99, 161.43, 158.82, 157.15, 140.66, 
122.83, 120.47, 119.94, 86.05, 43.48, 41.06; FT-IR (KBr) (cm-1): 3747, 3672.3 & 3650 (N-H) 
stretching, 2964.2 Ar-H (C-H stretch), 1584.5 (C=C) aromatic & (C=N) stretching, 1487, 1440.4 
& 1356.4 (C-H) bending, 922.2, 672.9 & 605.6 Ar-H (H2C=CH2 bending). 
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2.3.3 Synthesis of pyridyl-/pyrimidyl -piperazinyl derivatives: 
 
2.3.3.1 2-Bromo-1-(2, 3-dihydro-benzo [1, 4] dioxin-6-yl)-ethanone (26) derivatives: 
General Procedure: 
 
In a 25 ml round bottom flask, (0.5 g, 2.16 mmol) of the pyridyl-/pyrimidyl -piperazinyl 
derivative [1-(5-trifluoromethyl-pyridin-2-yl)-piperazine] (39) as example and (0.33 ml, 2.38 
mmol) of dry triethylamine (TEA) were mixed in 10 ml EA and cooled to 0 °C. 1.0 eq of 2-
bromo-1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethanone (26) (0.56 g, 2.16 mmol) was added and 
the reaction mixture was stirred at room temperature for the time needed to completion. The 
reaction progress was followed by TLC using (EA), or (EA:MeOH (90:10; v:v)). When the 
reaction was completed the mixture was partitioned between the aqueous and ethyl acetate 
phases (30 ml X 3). The organic fractions were collected and dried over anhydrous sodium 
sulfate. After filtering off the solids the volatiles were evaporated to dryness under reduced 
pressure. The powder was finally afforded by re-crystallization using ethanol as solvent to give 
the purified desired product.   
 
2.3.3.1.1 1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-[4-(5-trifluoromethyl-pyridin-2-yl)-
piperazin-1-yl]-ethanone {MYJ-7 (45)}: 
 
TLC (EA), Rf = 5.7/8.4 = 0.68; yellowish crystals; yield: 0.39 g (44.8%); 1H-NMR 300 MHz 
(CDCl3) (ppm) 2.65-2.75 (m, 4H), 3.70-3.75 (m, 4H),  3.75-3.80 (s, 1H), 4.25-4.30 (t, 4H), 
6.60-6.65 (dd, 1H), 6.85-6.90 (dd, 1H), 7.53 (m,1H), 7.55 (d, 1H), 7.59 (d,1H), 8.35-8.40 (s, 
1H); FT-IR (KBr) (cm-1): 2898.3 Ar-H (C-H stretch), 1675.3, 1614.4 (C=O), 1509.4(C=C) 
aromatic & (C=N) stretching, 1461, 1432.9 & 1388 (C-H) bending, 777.7, 744.5, 672, 624.7 & 
558.8 Ar-H (H2C=CH2 bending). 
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2.3.3.1.2 1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-(4-pyridin-2-yl-piperazin-1-yl)-ethanone 
{MYJ-10 (48)}: 
 
TLC (EA), Rf = 4.5/8.4 = 0.54; yellowish crystals; yield: 0.45 g (43.3%); 1H-NMR 300 MHz 
(CDCl3)  (ppm) 2.65-2.70 (t, 4H), 3.55-3.60 (t, 4H), 3.76 (s, 1H), 4.25-4.30 (dd, 4H), 6.59-6.64 
(m, 2H), 6.88-6.90 (d, 1H), 7.50-7.55 (d, 1H), 7.55-7.60 (t,2H), 8.15 (d,1H). There are some 
more peaks in the NMR spectrum belonging to impurities; FT-IR (KBr) (cm-1): 2994.7 Ar-H (C-
H stretch), 2824 CH2, CH3 (C-H stretch), 1678 (C=O), 1584 (C=C) aromatic & (C=N) stretching, 
1480, 1435.5 & 1381.5 (C-H) bending, 936, 743.8, 604 & 560.5 Ar-H (H2C=CH2 bending). 
 
2.3.3.1.3 1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-(4-pyridin-4-yl-piperazin-1-yl)-ethanone 
{MYJ-13 (51)}: 
 
TLC (EA:MeOH (90:10; v:v)), Rf = 2.8/8.2 = 0.34; yellowish crystals; yield: 0.55 g (52.9%); 
1H-NMR 300 MHz (CDCl3)  (ppm) 2.70-2.75 (t, 4H), 3.40 (t, 4H), 3.75-3.80 (s, 2H), 4.30 (m, 
4H), 6.65-6.70 (d, 2H), 6.90-6.95 (d, 1H), 7.54-7.57 (d, 1H), 7.57-7.60 (s, 1H), 8.25-8.30 (d,2H); 
FT- IR (KBr) (cm-1): 3000 Ar-H (C-H stretch), 2941.5, 2887.7, 2850.6 & 2799.1 CH2, CH3 (C-H 
stretch), 1692 (C=O), 1593.5, 1544.3 & 1506.5 (C=C) aromatic & (C=N) stretching, 1444.5, 
1392.5 & 1375 (C-H) bending, 948.9, 671.2, 645.7, 602.1 & 553.2 Ar-H (H2C=CH2 bending). 
 
2.3.3.1.4 1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-(4-pyrimidin-2-yl-piperazin-1-yl)-
ethanone {MYJ-15 (53)}: 
 
TLC (EA:MeOH (90:10; v:v)), Rf = 2.8/8.3 = 0.34; yellowish crystals ; yield: 0.457 g (44.1%); 
1H-NMR 300 MHz (CDCl3)  (ppm) 2.65-2.70 (t, 4H), 3.75-3.80 (s, 2H), 3.85-3.90 (t, 4H), 4.30 
(m, 4H), 6.45-6.50 (t, 1H), 6.90 (d, 1H), 7.55 (d, 1H), 7.58 (s, 1H), 8.30 (d, 2H); FT-IR (KBr) 
(cm-1): 3121, 2992 Ar-H (C-H stretch), 2943.8, 2874.5 & 2824.6 CH2, CH3 (C-H stretch), 1667 
(C=O), 1584.5, 1546 (C=C) aromatic & (C=N) stretching, 1497.5, 1450, 1358 & 1309 (C-H) 
bending, 851, 751.5, 713.7, 577.2 & 518.2 Ar-H (H2C=CH2 bending); MS (ESI) m/z calculated 
for C18H20N4O3 340.38, found 341.08 (M +H)
 +. 
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2.3.3.2 Benzofuran-2- carboxylic acid (43) derivatives: 
General Procedure: 
 
In a 25 ml round bottom flask, (0.2 g, 1.2 mmol) of benzofuran-2- carboxylic acid (43), (0.28 g, 
1.36 mmol) DCC and (0.16 g, 1.36 mmol) NHS were mixed in 5-10 ml DMF. The reaction 
mixture was stirred at room temperature overnight. Then 1.0 eq (0.28 g, 1.2 mmol) of the 
pyridyl-/pyrimidyl-piperazinyl derivative [1-(5-trifluoromethyl-pyridin-2-yl)-piperazine] (39) as 
example was added to the reaction mixture. The reaction progress was followed by TLC using 
(EA). When the reaction was completed DMF was evaporated under reduced pressure to dryness 
and the powder was finally afforded by re-crystallization using ethanol as solvent to give the 
purified desired product.   
 
2.3.3.2.1 Benzofuran-2-yl-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-methanone 
{MYJ-8 (46)}: 
 
TLC (EA), Rf = 6.7/8.3 = 0.81; white crystals; yield: 0.203 g (43.9%); 1H-NMR 300 MHz 
(CDCl3) (ppm) 3.75-3.80 (t, 4H),  4.00 (s, 4H), 6.65-6.70 (d, 1H), 7.30-7.35 (t, 1H), 7.35-7.40 
(t, 1H), 7.40-7.45(d, 1H), 7.50-7.55 (d, 1H), 7.66 (s, 1H), 7.69-7.70 (d, 1H); FT-IR (KBr) (cm-1): 
3003, 2943.6 Ar-H (C-H stretch), 2853.9 CH2, CH3 (C-H stretch), 1613.5 (C=O), 1566.4, 1508.2 
(C=C) aromatic & (C=N) stretching, 1477.2, 1463.1, 1444.7 & 1388.1 (C-H) bending, 950.2, 
860, 832.8, 672.8 & 645 Ar-H (H2C=CH2 bending). 
 
2.3.3.2.2 Benzofuran-2-yl-(4-pyridin-2-yl-piperazin-1-yl)-methanone {MYJ-9 (47)}: 
 
TLC (EA), Rf = 5.8/8.2 = 0.71; white crystals; yield: 0.129 g (34.01%); 1H-NMR 300 MHz 
(CDCl3)  (ppm) 3.65-3.70 (s, 4H), 3.95-3.40 (s, 4H), 6.65-6.70 (m, 2H), 7.30-7.35 (t, 1H), 7.35-
7.40 (t, 1H), 7.40-7.45 (t, 1H), 7.50-7.55 (m, 2H), 7.65-7.70 (d, 1H), 8.22 (m, 1H); FT-IR (KBr) 
(cm-1): 3004.1 Ar-H (C-H stretch), 2929.4, 2851 CH2, CH3 (C-H stretch), 1614.4 (C=O), 1481.6 
(C=C) aromatic & (C=N) stretching, 1439.3, 1382.1 & 1311.6 (C-H) bending, 979.4, 860.6, 
834.2, 672.6 & 522.5 Ar-H (H2C=CH2 bending). 
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2.3.3.2.3 Benzofuran-2-yl-(4-phenyl-piperazin-1-yl)-methanone {MYJ-12 (50)}: 
 
TLC (EA), Rf = 6.7/8.3 = 0.81; white to slightly yellowish crystals; yield: 0.313 g (82.8%); 1H-
NMR 300 MHz (CDCl3)  (ppm) 3.25-3.30 (t, 4H), 4.00-4.05 (s, 4H), 6.90-6.95 (m, 3H), 7.28 (s, 
1H), 7.30-7.35 (t, 2H), 7.36 (t, 1H), 7.40-7.45(t, 1H), 7.54 (d, 1H), 7.67 (d, 1H); FT-IR (KBr) 
(cm-1): 3036.2 Ar-H (C-H stretch), 2929, 2852 CH2, CH3 (C-H stretch), 1599.5 (C=O), 1439, 
1346.7 & 1312 (C-H) bending, 968.3, 917, 865, 568.6, 538.4 & 518.4 Ar-H (H2C=CH2 bending). 
 
2.3.3.3 6-Methoxy-Benzofuran-2- carboxylic acid (44) derivatives: 
General Procedure: 
 
In a 25 ml round bottom flask, (0.2 g, 1.04 mmol) of 6-methoxy-benzofuran-2-carboxylic acid 
(44), (0.24 g, 1.14 mmol) DCC and (0.13 g, 1.14 mmol) NHS were mixed in 5-10 ml DMF. The 
reaction mixture was stirred at room temperature overnight. Then 1.0 eq (0.24 g, 1.04 mmol) of 
the pyridyl-/pyrimidyl-piperazinyl derivative [1-(5-trifluoromethyl-pyridin-2-yl)-piperazine] (39) 
as example was added to the reaction mixture. The reaction progress was followed by TLC using 
(EA). When the reaction was completed DMF was evaporated under reduced pressure to dryness 
and the powder was finally afforded by re-crystallization using ethanol as solvent to give the 
purified desired product.   
 
2.3.3.3.1 (6-Methoxybenzofuran-2-yl)-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-
methanone {MYJ-11 (49)}: 
 
TLC (EA), Rf = 6.4/8.2 = 0.78; slightly brownish crystals; yield: 0.275 g (65.2%); 1H-NMR 300 
MHz (CDCl3)  (ppm) 3.75-3.80 (t, 4H), 3.85-3.90 (d, 3H), 4.00 (s, 4H), 6.65-6.70 (d, 1H), 6.95 
(d, 1H), 7.00-7.05 (s,1H), 7.30-7.35 (d, 1H), 7.50-7.55 (d, 1H), 7.65-7.70 (d, 1H), 8.40-8.45 (s, 
1H); FT-IR (KBr) (cm-1): 3126.7 Ar-H (C-H stretch), 3034.7, 2925 & 2852.5 CH2, CH3 (C-H 
stretch), 1588 (C=O), 1438, 1319.5 (C-H) bending, 967.7, 950.2, 837.7 & 537.7 Ar-H (H2C=CH2 
bending). 
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2.3.3.3.2 (6-Methoxybenzofuran-2-yl) - (4-pyrimidin-2-ylpiperazin-1-yl)-methanone {MYJ-
14 (52)}: 
 
TLC (EA), Rf = 4.9/8.3 = 0.59; slightly brownish crystals; yield: 0.192 g (54.5%); 1H-NMR 300 
MHz (CDCl3)  (ppm) 3.85-3.90 (s, 3H), 3.90-3.95 (s, 8H), 6.55 (t, 1H), 6.90-6.95 (d, 1H), 7.00-
7.05(s, 1H), 7.25-7.30 (s, 1H), 7.50-7.55 (d, 1H), 8.30-8.35 (dd, 2H); FT-IR (KBr) (cm-1): 3119.6 
Ar-H (C-H stretch), 2929.5, 2851.4 CH2, CH3 (C-H stretch), 1549.5 (C=O), 1500 (C=C) 
aromatic & (C=N) stretching, 1438.5, 1361.5 & 1311.9 (C-H) bending, 892.7, 777, 738.7, 678.3 
& 529.4 Ar-H (H2C=CH2 bending). 
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Chapter Three 
 
 
 
Results and Discussion 

3. Results and Discussion: 
 
The major challenge in developing kinase inhibitor is to achieve selective inhibition of kinase(s) 
associated with the disease (cancer). In contrast to ATP-binding site which is common to all 
kinases and is thus difficult to achieve selectivity, allosteric sites are likely to be selective and 
specific to individual kinases and by that it represents a promising strategy for the design of 
kinase inhibitors with improved selectivity and also utility in overcoming drug resistance. 
 
In this research our efforts have been invested in synthesizing small molecules that act as 
allosteric inhibitors of Bcr-Abl through binding to the myristoyl binding pocket MBP. 
All the compounds (including intermediates) planned to be prepared during the execution of the 
project in hand are designed, prepared, purified using chromatography techniques and 
characterized using physical methods that include nuclear magnetic resonance (1H-, 13C-, COSY 
and HMBC NMR), Fourier transform infrared spectroscopy (FTIR), Electrospray ionization 
mass spectrometry (ESIMS) and then tested for their biological activity and on the basis of the 
results new generations of compounds are designed, prepared and tested.  
 
3.1 Chemical synthesis of compounds: 
 
Three groups of compounds have been synthesized in the course of the proposed study: 
 
3.1.1 GNF-2 and GNF-5 analogues: 
 
With knowledge of the two known MBP selective inhibitors GNF-2 and -5 in hand, and knowing 
that the 4-trifluoromethoxyaniline at 6-position of the pyrimidine core is an obligate structural 
feature for achieving submicromolar potency as a cellular Bcr-Abl inhibitor and that the 
pyrimidine ring can be elaborated to include a variety of other heterocyclic ring systems [83], we 
aimed at exploring the possibility of introducing different structural moieties at the 4-position of 
the pyrimidine  heterocyclic moiety. To that end we plan to replace the 3-benzamide moiety with 
piperazinyl-derivatives (see Figure 3.1 below).  
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R = H, GNF-2, (8)
R = (CH2)2-OH, GNF-5 (9)
N N
N
H
O
F
F
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F
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Conserved part Conserved part
GNF-2/-5 analogues
 
Figure 3.1: Rational of synthesizing the GNF-2/-5 analogues. 
 
Several analogues including aromatic derivatives conjugated via an amide group [benzoyl (21) 
and dimethoxy benzoyl (22)], alkyl chain linker such as 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)ethanone  (26), or  via sulfonamide group [mesyl (27) and tosyl (55)] have been synthesized 
following the procedures depicted in Schemes 1 and 2 below. 
 
3.1.1.1 Synthesis of (6-piperazin-1-yl-pyrimidin-4-yl)-(4-trifluoromethoxyphenyl)-
ammonium.hydrochloride (18) and (6-piperazin-1-ylpyrimidin-4-yl)-(4-fluorophenyl)-
ammonium.hydrochloride (19): 
 
These precursors 18 and 19 were prepared starting from the commercially available 4,6-
dichloropyrimidine (10)  that was reacted with  p-trifluoromethoxyaniline (11) or 4-fluoroaniline 
(12) under basic conditions using DIPEA to get the white fluffy amines 13 and 14 in 80% and 
85% yields, respectively. 
These corresponding 6-substituted pyrimidines 13 and 14 were then subjected to nucleophilic 
displacement of the chloro group by piperazine-1-carboxylic acid tert-butyl ester (BOC-
piperazine) (15) under elevated temperature for 12 h. The BOC was then cleaved under acidic 
conditions to afford the amine free form of piperazinylpyrimidine as white salts 18 and 19 in 
75% and 80% yields, respectively. 
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Scheme 1: Representative procedure for the synthesis of salts 18 and 19: 
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R
N N
N
NH.5HCl
(15)
(18): R= OCF 3
(19): R = F
 
 
Reagents and conditions: a) DIPEA, reflux 2 h, column chromatography CHCl3; b) K2CO3,   
                                          reflux 12 h, column chromatography CHCl3:hexane (50: 50; v:v); c)      
                                          EtOH, HCl, stirring 1 h, cooling, filtration. 
 
3.1.1.2 Synthesis of GNF-2/ GNF-5 analogues (MYJ-16 -MYJ-23 (28-35) and MYJ-25 & 
MYJ-26 (57 & 56)): 
 
The synthesis of these target compounds was obtained by conjugating the terminal piperazinyl 
secondary amine in 18 or 19 with the corresponding acyl halide 21, 22, 23, 24, 25 or 54, sulfonyl 
halide 27 or 55, or 2-bromo-1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethanone (26) under basic 
conditions using TEA  to afford the desired products 28-35 and 57& 56. 
Reactions were carried out in DMF at room temperature and the final products were purified 
using column chromatography to give 28, 29, 30, 31, 32, 33, 34, 35, 57 and 56 final products in 
44.9%, 41.0%, 52.0%, 65.0%, 91.0%, 93.0%, 45.0%, 95.0%, 64.9% and 80.2% yields, 
respectively.  
The final products were characterized by 1H-NMR, 13C-NMR, FT-IR and ESIMS spectroscopy. 
To confirm the purity, the proton sequences, protons’ spin-spin coupling and the proton-carbon 
correlations COSY and HMBC 2D-NMR were done further for 28 (Figure 2.1, Table 2.1). 
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Scheme 2: Representative procedure for the synthesis of GNF-2/-5 analogues: 
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Reagents and conditions: a) TEA, stirring 6 h for 29 and 31, 24 h for 32, 33, 35, 57 & 56, 48 h 
for 28, 30 and 34 8  at r.t, evaporation, extraction, column 
chromatography CHCl3: hexane (50: 50; v:v) for 29, 30 & 31, CHCl3: 
hexane (70: 30; v:v) for 28, CHCl3: Eth.Ac. (80: 20; v:v) for 34 & 35, 
CHCl3: Eth.Ac. (70: 30; v:v) for 57, CHCl3 for 32 & 33, recrystalization 
from EtOH for 56. 
 
3.1.1.3 Synthesis of aromatic acyl halides: 
 
The acyl halides were prepared by reaction of the corresponding carboxylic acid 58, 59, 60, 61 or 
62 with excess oxalyl chloride at room temperature and inert conditions. The reaction progress 
was followed by TLC using CHCl3 for compounds 21, 24, 25 and 54 and EA for compounds 22 
and 23.  
All acid chlorides were obtained in high yields 96% for 22, 25 & 54; 95% for 24; 97% for 23 and 
characterized by 1H-NMR.  Acid chlorides were used without further purification. 
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Scheme 3: Representative procedure for the synthesis of aromatic fatty acids halide: 22, 23, 24, 
25, and 54: 
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Reagents and conditions: a) 2.0 eq oxalyl chloride, 20 ml dry DCM, stirring 24 h at r.t, 
evaporation. 
 
3.1.1.4 Synthesis of [6-(4-phenyl-piperazin-1-yl)-pyrimidin-4-yl]-(4-trifluoromethoxy-
phenyl)-amine MYJ-1 (20): 
 
Compound 20 was prepared in the same manner described in Scheme 1, starting from the 
commercially available 4,6-dichloropyrimidine (10) which was reacted with  p-
trifluoromethoxyaniline (11) under basic conditions using DIPEA  to get a white fluffy amine 13 
in a high yield (80%). 
Amine 13 was subjected to nucleophilic displacement of the chloro leaving group by 
phenylpiperazine (36) using potassium carbonate as a base under refluxing DMF. 
The product was purified by column chromatography using CHCl3:hexane (50:50; v:v), obtained 
by 52.0% yield and characterized by 1H-NMR and FT-IR spectroscopy. 
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3.1.2 Piperazine symmetrical analogues: 
 
As we mentioned above, we investigated the consequences of replacing the 3-benzamide moiety 
with piperazinyl-derivatives. Considering that the lowest energy pose places GNF-2 in an 
extended trans conformation with the 4-trifluoromethoxyaniline pointed toward the bottom of the 
pocket [83], we aimed to synthesize a symmetrical extended analogue by binding the 4-
trifluoromethoxyaniline from both sides to the piperazine, which could noticeably enhance 
binding affinity toward the MBP. 
?
Synthesis of 1,4-Piperazine, bis {(6-Pyrimidin)-(4-trifluoromethoxy-phenyl)-amine} MYJ-
24 (38): 
 
The synthesis of this final compound was a one step reaction, simply by reacting 1.0 equivalent 
of the commercially available piperazine (37) and 2.0 equivalents (6-chloropyrimidin-4-yl)-(4-
trifluoromethoxyphenyl) amine (13) under basic condition and elevated temperature using DMF 
as solvent. 
The completion of the reaction was indicated by TLC using EA and the product was purified by 
column chromatography using CHCl3, obtained by 45.0% yield and characterized by 
1H-, 13C- 
NMR and FT-IR spectroscopy. 
 
Scheme 4: Representative procedure for the synthesis of piperazine symmetrical analogues:  
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Reagents and conditions: a) K2CO3, reflux at 100 °C for 12 h, extraction, column     
                                           chromatography using CHCl3. 
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3.1.3 Pyridyl-/Pyrimidyl-piperazinyl derivatives: 
 
Assisted by computational chemistry techniques several 2-, 4-pyridyl piperazinyl (39, 40 or 41) 
and 2-pyrimidyl piperazinyl derivatives (42) were proposed as having binding affinity to the 
MBP.  
To explore the diversity of the MBP inhibitors, derivatives including benzofuran-2-carboxylic 
acid (43), 6-methoxybenzofuran-2-carboxylic acid (44) and 1-(2,3-dihydrobenzo[b][1,4]dioxin-
6-yl)ethanone (26) with variations in the position of the pyridine or pyrimidine amine were all 
examined. 
To evaluate the effect of pyridine heterocycle on the activity, derivative of phenylpiperazine (36) 
was also synthesized and examined. For the synthesis of these compounds see general procedure 
depicted in Scheme 5 below. 
 
3.1.3.1 Synthesis of benzofuran-2-carboxylic acid (43), 6-methoxybenzofuran-2-carboxylic 
acid (44) derivatives: 
 
Compound 43 or 44 were coupled to 2- or 4-pyridylpiperazinyl (39, 40 or 41) or 2-
pyrimidylpiperazinyl (42) or phenyl piperazine (36), respectively to get the desired products in  
two steps. First; the desired carboxylic acid was mixed and stirred with the coupling agent DCC 
using NHS as coupling agent at room temperature overnight. Second; the resulting intermediate 
was coupled to the corresponded 39, 40, 41; 42 or 36 to get the desired product which was 
afforded by re-crystallization using ethanol as solvent. 
The resulted derivatives 46, 47, 49, 50 and 52 were obtained as crystals in 43.9%, 34.01%, 
65.2%, 82.8% and 54.5% yields, respectively. 
 
3.1.3.2 Synthesis of 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanone (26) derivatives: 
 
The commercially available compound 26 underwent nucleophilic substitution of the bromo 
leaving group by the corresponding pyridyl or pyrimidylpiperazinyl derivative 39, 40, 41 or 42 
using TEA as a base at room temperature the time needed for completion. 
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The desired product was then purified by extraction, evaporation and re-crystallization using 
ethanol as solvent. 
The resulting derivatives 45, 48, 51 and 53 were obtained as crystals in 44.8%, 43.3%, 52.9%, 
and 44.1% yields, respectively. 
 
Scheme 5: Representative procedure for the synthesis of Pyridyl-/Pyrimidyl-piperazinyl 
derivatives: 
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Reagents and conditions: a) DCC, NHS, 24 h at r.t for 46, 47, 49, 50 & 52; b) evaporation; c) 
recrystallization by EtOH; d) TEA, stirring 12 h for 45, 15 h for 48 
and 51, 24 h for 53 at r.t.; e) extraction, evaporation; f) 
recrystallization from EtOH. 
 
3.2 Biological evaluation of novel allosteric inhibitors of Bcr-Abl: 
 
3.2.1 In-vitro assessment of cellular auto-phosphorylation activity in Ba/F3 Bcr-Abl cells: 
 
To evaluate the cellular auto-phosphorylation activity of the different compounds we utilized 
Ba/F3, murine B lymphocytes cells, transfected with Bcr-Abl gene. We noticed that 
responsiveness to allosteric inhibitors such as GNF-2 is a cell-type specific and also depends on 

the size of Bcr-Abl. Figure 3.2 demonstrated that while activity of Imatinib, ATP competitor of 
Abl, was comparable against p185 and p210 Bcr-Abl, activity of GNF-2 was varied. GNF-2 was 
less effective in inhibiting cellular auto-phosphorylation of Ba/F3 transfected with p210 Bcr-Abl 
compared to p185 Bcr-Abl.  
 
 
 
 
Figure 3.2: Auto-phosphorylation inhibition of STAT5 and p185, p210 Bcr-Abl by GNF-2. 
 
3.2.2 Inhibition of cellular auto-phosphorylation of the native Bcr-Abl: 
 
We screened our compounds for inhibitory activity of the p185 Bcr-Abl auto-phosphorylation 
function. Compounds were evaluated in duplicate in two or more concentrations. Bcr-Abl 
transfected cells were treated for one hour and viability of the cells were determined using 
Trypan blue exclusion assay and the lysates were used to evaluate cellular auto-phosphorylation 
as previously described. See Table 3.1 and Figure 3.3 below. 
Results of tested compounds demonstrated that MYJ-1 (20), MYJ-2 (16) and MYJ-17 (29) 
exhibited some activities in the Ba/F3 Bcr-Abl cell lines at high concentrations, and that MYJ-16 
(28) shows significant activity at different concentrations comparing to GNF-2 (8).      
 
 
 

Table 3.1: The percentage values of the Ba/F3 P185-tyrosine inhibition by the MYJ’s 
compounds: 
Compound 
No. 
Compound 
Code 
Structure Concentrations 
% pTyr 
Inhibition 
50 µ M 57.53 
10 µ M 43.34 8 GNF-2 
 
 
2 µ M 39.64 
200 µ M 70.62 
20 µ M 43.81 20 MYJ-1 
 2 µ M 4.48 
200 µ M 69.33 
20 µ M 21.79 16 MYJ-2 
 
 
2 µ M 4.52 
200 µ M 24.1 
45 MYJ-7 
 
 
50 µ M 9.59 
200 µ M 16.85 
46 MYJ-8 
 
 
50 µ M 11.93 
200 µ M 13.25 
47 MYJ-9 
 
 
50 µ M 6.67 
200 µ M -2.58 
48 MYJ-10 
 
 
50 µ M 7.95 
200 µ M 32.64 
49 MYJ-11 
 
 
50 µ M 8.57 
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Table 3.1, cont.: 
 
200 µ M -8.82 
50 MYJ-12 
 
 
50 µ M -6.75 
200 µ M 15.47 
51 MYJ-13 
 
 
50 µ M 8.68 
200 µ M 15.13 
52 MYJ-14 
 
 
50 µ M -3.93 
200 µ M 20.18 
53 MYJ-15 
 
 
50 µ M -1.85 
200 µ M 95.58 
100 µ M 94.68 
50 µ M 75.36 
25 µ M 64.47 
10 µ M 52.35 
28 
MYJ-16 
 
 
 
2 µ M 30.77 
200 µ M 58.15 
20 µ M 20.59 29 MYJ-17 
 
 
2 µ M -0.24 
30 MYJ-18 
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Table 3.1, cont.: 
 
32 MYJ-20 
 
---- ND 
33 MYJ-21 
 
---- ND 
34 MYJ-22 
 
 
---- ND 
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Figure 3.3: Auto-phosphorylation inhibition of p185 Bcr-Abl by MYJ’s compounds compared by 
GNF-2. 
 
3.2.3 Inhibition of cellular auto-phosphorylation of the native and T315I mutated Bcr-Abl 
form by MYJ-16 (28): 
 
Results shown in Figure 3.3 above demonstrated that MYJ-16 (28) was the most active 
compound in inhibiting auto-phosphorylation of native Bcr-Abl, thus it was also tested for its 
ability to affect auto-phosphorylation of T315I mutated Bcr-Abl form. 
Results shown in Figure 3.4 illustrated that Imatinib at 1 µM and GNF-2 at 50 µM were active in 
inhibiting Bcr-Abl auto-phosphorylation in Ba/F3 cells carrying native Bcr-Abl, but failed to do 
so in cells carrying the T315I mutated Bcr-Abl.  
In contrast Figure 3.4 (a) and (b) showed that treatment of Ba/F3 cells containing native and 
T315I mutated Bcr-Abl with MYJ-16 (28) caused gradual elimination of Bcr-Abl apparently by 
degradation mechanism. 28 exhibited a dose-dependent effect and exerted its effect in all Ba/F3 
cells tested.  
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(a)  
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Inhibition of Bcr-Abl cellular auto-phosphorylation and T315I mutated Bcr-Abl by MYJ-16 
(28) compound. (a) Percentage of Bcr-Abl auto-phosphorylation (violet) and T315I mutated 
Bcr-Abl inhibition (purple), (b) Western blot of inhibition of Bcr-Abl auto-phosphorylation 
by MYJ-16 (28) for cells carrying native and T315I mutated Bcr-Abl forms. 
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3.2.4 Clonigenicity Inhibition:  
 
Anchorage-independent growth of cells is a typical characteristic of the tumorigenicity of cancer 
cells in-vitro [91]. Thus, we tested the ability of different compounds to affect clonigenicity of 
Ba/F3 harboring native and T315I Bcr-Abl constructs. Figure 3.5 showed that Imatinib at 1 µM 
and GNF-2 at 10 µM were active in inhibiting clonigenicity of Ba/F3 cells carrying native Bcr-
Abl, but not T315I mutated Bcr-Abl. GNF-2 at higher concentration (25 µM) also was active in 
inhibiting Ba/F3 cells carrying native Bcr-Abl, but T315I mutated Bcr-Abl form by about 27% 
only.  
MYJ-16 (28) showed variable potency in inhibiting Ba/F3 cells carrying Bcr-Abl constructs. 
Interestingly, 28 at 25 µM showed nearly comparable activity against clonigenicity of Ba/F3 
harboring native or T315I Bcr-Abl constructs. 
This result is probably a proof that 28 compound do indeed bind to the myristate pocket, and that 
it’s binding in allosteric manner induces changes in the dynamics properties of the ATP site in 
both wild type and T315I forms of Bcr-Abl, which indicates that T315I mutation did not alter the 
ability of 28 to do changes in the ATP site that located approximately 30 	 from the MBP which 
is 28 site of interaction as we suppose.  
And if so, it is very worthy to test 28 for the cellular inhibition of the T315I in combination with 
nilotinib or dasatinib or other ATP competitive inhibitor which could be very effective in 
suppressing T315I both in-vitro and in-vivo at lower concentrations. 
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Figure 3.5: Clonigenicity Inhibition of Ba/F3 cells carrying the native and T315I mutated Bcr-
Abl constructs by Imatinib, GNF-2 (8) and MYJ-16 (28) compound using different 
concentrations. 
 
3.2.5 Evaluation of the effect of MYJ’s compounds on the inhibition of proliferation of ALL 
cell lines Sup-B15: 
 
The ability of few MYJ compounds (MYJ-16 (28), MYJ-18 (30) and MYJ-19 (31)) to inhibit 
proliferation of Sup-B15 ALL cell lines was evaluated. .  
Table 3.2 and Figure 3.6 below showed that 28, 30 & 31 compounds exhibited a dose-dependent 
effect to inhibit proliferation of ALL cell lines Sup-B15 comparing with GNF-2 (8). 
Compound 28 was more active in inhibiting proliferation of ALL cell lines Sup-B15 at lower 
concentrations comparing to 30 and 31.   
 
 
 

Table 3.2: The percentage values of inhibition of ALL cell lines Sup-B15 by the MYJ’s 
compounds comparing to GNF-2: 
 
Compound 
No. 
Compound 
Code 
Structure Concentrations 
% pTyr 
Inhibition 
1 µ M 48.94 
8 GNF-2 
 
 
0.2 µ M 11.74 
200 µ M 95.61 
50 µ M 68.63 
10 µ M 64.14 
28 MYJ-16 
 
 
2 µ M 49.51 
50 µ M 67.36 
10 µ M 61.28 30 MYJ-18 
 
 
2 µ M 43.84 
50 µ M 61.96 
10 µ M 42.25 31 MYJ-19 
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Figure 3.6: Inhibition of ALL cell lines Sup-B15 by the MYJ-16 (28), MYJ-18 (30) and MYJ-
19 (31) compounds. 
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3.2.4 Bcr-Abl Structure-Activity Relationships (SAR) of MYJ compounds: 
 
We have presented a comprehensive exploration of Bcr-Abl targeted ligands that have binding 
affinity to the MBP. Three groups of compounds have been synthesized in this proposed study 
and evaluated for their potency to inhibit the auto-phosphorylation in Ba/F3 Bcr-Abl transfected 
cells carrying either the native or the T315I mutated form.  
 
3.2.4.1 GNF-2 and GNF-5 subclass: 
 
Depending on the two lead compounds GNF-2 and -5 that specifically inhibited Bcr-Abl in an 
allosteric manner, keeping the 4,6- pyrimidine substitution pattern with the 
trifluoromethoxyaniline group at para position, and adding several structural moieties  at the 4-
position of the pyrimidine ring using different piperazinyl-derivatives, 12 analogues have been 
synthesized,  purified using chromatography techniques, characterized by 1H-NMR, 13C-NMR, 
{COSY and HMBC 2D-NMR  for MYJ-16 (28)}, FT-IR and ESIMS spectroscopy and 
investigated for having activity as cellular Bcr-Abl inhibitors. 
Results of the tested compounds demonstrated that compounds containing phenyl piperazine 
such as MYJ-1 (20), piperazine-1-carboxylic acid tert-butyl ester such as MYJ-2 (16) or 2-
bromo-1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethanone such as MYJ-17 (29)  at the 4-position of 
the pyrimidine ring exhibit limited activity against Ba/F3 P185 kinase. And that compound MYJ-
16 (28) having 3,4-dimethoxy-benzoyl at pyrimidine  4 position have shown impressive activity 
at different concentrations compared to GNF-2 (8).      
Compound 28 showed nearly comparable activity against clonigenicity of Ba/F3 harboring 
native and T315I Bcr-Abl constructs at 25µM concentration and this result suggested that this 
myristate ligand can display a differential ability to synergize with ATP-competitive inhibitors to 
inhibit both wild-type and T315I Bcr-Abl mutant and also decrease the number of resistant 
clones that emerge as a response to continued exposure to a single agent. 
Compound 28 was also more active in inhibiting proliferation of ALL cell lines Sup-B15 at 
lower concentrations comparing to MYJ-18 (30) and MYJ-19 (31) having benzoyl and 4-
trifluoromethyl benzoyl, respectively at the pyrimidine  4 position that showed activity at higher 
concentrations.   

The biological activity for the other analogues will be assessed against Bcr-Abl transfected cells 
in the near future. 
 
3.2.4.2 Piperazine symmetrical analogues subclass: 
 
By knowing that the 4-trifluoromethoxyaniline is a necessary part for achieving potency as a 
Bcr-Abl inhibitor, we envisaged that binding this ligand from both sides to the piperazine to have 
a symmetrical analogue would enhance the affinity and increase the number of hydrogen bonds 
with the MBP. To that end MYJ-24 (38) was synthesized and the biological activity will be 
assessed against Bcr-Abl transfected cells in the near future. 
 
3.2.4.3 Pyridyl-/Pyrimidylpiperazinyl subclass: 
 
According to computational chemistry techniques that showed that compounds sharing 2-, 4-
pyridyl piperazinyl (39, 40 or 41) and 2-pyrimidylpiperazinyl (42) scaffolds supposed to have 
binding affinity to the MBP, nine compounds were synthesized MYJ-7~MYJ-15 (45-53,  
respectively) and assessed for their ability to inhibit the auto-phosphorylation in Ba/F3 p185 Bcr-
Abl transfected cells. 
Results showed that none of these nine compounds exert any auto-phosphorylation inhibitory 
effect when compared to GNF-2 (8) or Imatinib at different concentrations. 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
Chapter Four 
 
 
 
Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

4. Conclusion: 
 
Despite the impressive success of imatinib which revolutionized the treatment of CML, 5–10% 
clinical relapse due to drug resistance has been documented following long-term imatinib 
therapy in CML T315I. Second and third generations of tyrosine kinase inhibitors have been 
developed to obtain an increased potency and a broad range of activity against known imatinib-
resistant mutants, but none was effective against the T315I recalcitrant mutant. 
A new class of allosteric Bcr-Abl inhibitors appeared, and represented a promising new strategy 
for the design of kinase inhibitors with improved selectivity and utility in overcoming drug 
resistance, two promising lead compounds GNF-2 /-5 approved to inhibit wild-type Bcr-Abl and 
many clinically relevant imatinib resistant mutants. 
These MBP inhibitors represent not only a safe and effective therapy for CML, but also a proof-
of-principle that targeting a single protein can be an effective therapeutic strategy in certain types 
of cancers, also the ability of these compounds to synergize with ATP-competitive inhibitors to 
inhibit the growth of cells transformed with Bcr-Abl mutants made this new therapeutic modality 
a promising approach. 
In our research we focused on the myristate pocket as the prime candidate for the GNF-2 /-5 
binding site, and accordingly many analogues were designed, synthesized, purified using 
chromatography techniques, characterized by 1H-NMR, 13C-NMR, FT-IR and ESIMS 
spectroscopy and tested for their biological activity against Ba/F3 harboring native and T315I 
Bcr-Abl. Results of tested compounds demonstrated that MYJ-1 (20), MYJ-2 (16) and MYJ-17 
(29) exhibited some activities against Ba/F3 P185-tyrosine and that MYJ-16 (28) having 3,4-
dimethoxy-benzoyl at pyrimidine  4 position shows impressive activity at different 
concentrations comparing to GNF-2 (8). 
Compound 28 showed nearly comparable activity against clonigenicity of Ba/F3 harboring 
native and T315I Bcr-Abl constructs at 25 µM concentration and this result indicates that this 
myristate ligand which binds in allosteric manner can induce changes in the dynamics properties 
of the ATP site in both wild type and T315I forms of Bcr-Abl, which suggests that it can display 
a differential ability to synergize with ATP-competitive inhibitors to inhibit the growth of cells 
transformed with Bcr-Abl mutants and likely to prevent or delay the emergence of resistance 
mutations. 

Compound 28 was also more active in inhibiting proliferation of ALL cell lines Sup-B15 at 
lower concentrations comparing to MYJ-18 (30) and MYJ-19 (31) that showed activity at higher 
concentrations.   
This work demonstrates that a variety of structures can effectively inhibit Bcr-Abl by 
presumably targeting myristate binding pocket and provides new leads for developing drugs to 
treat Bcr-Abl driven leukemia.  
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Appendices 
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Appendix 6.1: Nuclear magnetic resonance (1H-, 13C-, COSY & HMBC NMR) of compound MYJ-16 (28) 
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Appendix 6.2: Electrospray ionization mass spectrometry (ESIMS) of compounds MYJ-15 (53), MYJ-16 (28), MYJ-18 (30), MYJ-19 
(31) and MYJ-20 (32) 
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Appendix 6.3: Fourier transform infrared spectroscopy (FTIR) of compounds MYJ-11 (49), MYJ-16 (28), MYJ-18 (30), MYJ-20 
(32), MYJ-22 (34) and MYJ-24 (38) 
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Operator 73
Name
Sample 073 By Operator date Saturday, December 03 2011
Description
4000 5003500 3000 2500 2000 1500 1000
1.2
-0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
cm-1
%
T
MYJ-11
1588.00cm-1, 0.03%T
2925.00cm-1, 0.04%T
3329.00cm-1, 0.04%T
2852.50cm-1, 0.04%T 1241.50cm-1, 0.05%T
1088.50cm-1, 0.05%T
1438.00cm-1, 0.06%T 1319.50cm-1, 0.07%T
649.00cm-1, 0.08%T
1159.58cm-1, 0.11%T
1046.56cm-1, 0.15%T
892.77cm-1, 0.25%T3034.68cm-1, 0.33%T
812.12cm-1, 0.34%T
737.55cm-1, 0.37%T
837.71cm-1, 0.37%T
3126.74cm-1, 0.39%T
950.15cm-1, 0.44%T
537.69cm-1, 0.50%T
967.67cm-1, 0.53%T
2666.36cm-1, 0.58%T
3655.98cm-1, 1.05%T
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Operator 39
Name
Sample 039 By Operator date Tuesday, November 29 2011
Description
4000 5003500 3000 2500 2000 1500 1000
1.1
-0.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
cm-1
%
T
1235.00cm-1, 0.05%T
1510.50cm-1, 0.05%T
1602.00cm-1, 0.06%T
1434.00cm-1, 0.09%T
1001.07cm-1, 0.13%T
1301.00cm-1, 0.14%T
822.95cm-1, 0.15%T
1025.19cm-1, 0.16%T3322.56cm-1, 0.16%T
1333.23cm-1, 0.16%T
1381.44cm-1, 0.19%T
3197.37cm-1, 0.26%T
2964.98cm-1, 0.30%T
977.98cm-1, 0.30%T
773.95cm-1, 0.30%T
856.66cm-1, 0.31%T
3012.47cm-1, 0.34%T
2860.36cm-1, 0.34%T
701.47cm-1, 0.41%T
609.00cm-1, 0.44%T
669.21cm-1, 0.62%T
653.10cm-1, 0.62%T
514.19cm-1, 0.63%T
638.48cm-1, 0.63%T
527.61cm-1, 0.63%T
585.12cm-1, 0.68%T
569.17cm-1, 0.79%T
557.45cm-1, 0.81%T
MYJ-16
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Operator 57
Name
Sample 057 By Operator date Wednesday, November 30 2011
Description
4000 5003500 3000 2500 2000 1500 1000
1.0
0.1
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
cm-1
%
T
1259.00cm-1, 0.07%T
1509.00cm-1, 0.09%T
1600.50cm-1, 0.09%T3332.00cm-1, 0.09%T
804.00cm-1, 0.11%T
1161.93cm-1, 0.12%T
1017.45cm-1, 0.16%T
1453.79cm-1, 0.16%T
1361.62cm-1, 0.19%T
709.11cm-1, 0.24%T
3231.11cm-1, 0.27%T
977.23cm-1, 0.31%T
2964.34cm-1, 0.32%T
2853.93cm-1, 0.37%T
740.66cm-1, 0.41%T
926.04cm-1, 0.58%T
511.32cm-1, 0.61%T
602.64cm-1, 0.63%T
626.43cm-1, 0.67%T
534.20cm-1, 0.71%T
MYJ-18
 
NHO
F
F
F
N
N
N
O
N
	
Operator 56
Name
Sample 056 By Operator date Wednesday, November 30 2011
Description
4000 5003500 3000 2500 2000 1500 1000
1.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
cm-1
%
T
1152.00cm-1, 0.05%T
1585.00cm-1, 0.06%T 796.00cm-1, 0.07%T
1504.50cm-1, 0.07%T 1028.50cm-1, 0.08%T
1221.50cm-1, 0.10%T
1360.85cm-1, 0.11%T
2964.66cm-1, 0.15%T
972.77cm-1, 0.17%T
1457.79cm-1, 0.18%T
952.62cm-1, 0.22%T
519.42cm-1, 0.31%T
532.69cm-1, 0.31%T
507.78cm-1, 0.43%T
694.25cm-1, 0.44%T
604.82cm-1, 0.58%T
617.47cm-1, 0.63%T
634.90cm-1, 0.66%T
564.43cm-1, 0.83%T
MYJ-20
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Operator 62
Name
Sample 062 By Operator date Saturday, December 03 2011
Description
4000 5003500 3000 2500 2000 1500 1000
1.1
0.1
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
cm-1
%
T
MYJ-22
1262.50cm-1, 0.09%T
800.39cm-1, 0.10%T
1025.71cm-1, 0.11%T
1594.67cm-1, 0.12%T 1432.81cm-1, 0.15%T
1508.03cm-1, 0.19%T 1226.05cm-1, 0.20%T
2964.15cm-1, 0.24%T
1182.13cm-1, 0.34%T
876.65cm-1, 0.46%T
3650.13cm-1, 0.50%T3746.86cm-1, 0.50%T
3672.07cm-1, 0.51%T
3852.05cm-1, 0.54%T
616.41cm-1, 0.64%T
702.19cm-1, 0.68%T
2347.64cm-1, 0.72%T
517.35cm-1, 0.85%T
549.34cm-1, 0.88%T
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Operator 60
Name
Sample 060 By Operator date Wednesday, November 30 2011
Description
4000 5003500 3000 2500 2000 1500 1000
1.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
cm-1
%
T
1584.50cm-1, 0.04%T
1216.00cm-1, 0.06%T
802.50cm-1, 0.06%T
1034.50cm-1, 0.08%T
1487.00cm-1, 0.10%T
1440.44cm-1, 0.11%T
2964.22cm-1, 0.13%T
1356.35cm-1, 0.14%T
3649.98cm-1, 0.36%T
3746.99cm-1, 0.36%T
3672.34cm-1, 0.37%T
3854.41cm-1, 0.40%T
672.85cm-1, 0.47%T
922.17cm-1, 0.54%T
605.57cm-1, 0.67%T
MYJ-24
O F
FF
N N
N
H
N
OF
F F
NN
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N N
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